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INTRODUCTION 
 
An increasing number of men are diagnosed with prostate cancer each year. 
Prostate cancer is now the most common form of cancer in men and the second 
leading cause of cancer deaths after lung cancer.1 There is presently no efficient cure 
for disseminated, androgen-independent prostate cancer. Some of the major challenges 
of prostate cancer are to diagnose the cancer at the earliest possible stage and be able 
to characterize the molecular nature of the cancer tumour to discern between the 
patients who need active, invasive treatment versus those who will benefit from active 
surveillance. It would also be preferable to be able to tailor the treatment regime 
according to the nature of the tumour. Although of clinical diagnostic and prognostic 
value, the currently widely used PSA (prostate specific antigen) biomarker does not 
fulfil the above mentioned requirements, and there is an immense search for new more 
specific and sensitive biomarkers in order to provide the necessary information 
regarding screening, classification, prognosis and prediction. Our motivation to start 
genome-wide gene expression analysis of prostate cancer was the hope that this could 
be a very promising strategy to identify novel markers, to understand better the 
molecular mechanisms of prostate carcinogenesis and progression and that this might 
again be very useful for the discovery of potential therapeutic molecular targets. 
 
INCIDENCE  
  
In Norway, prostate cancer is the most frequent form of cancer in men, with 4168 out 
of 14000 new cases in 2008, which account for approximately 30 % of all cancers in 
men that year. Over the 5-year period 2004-2008 prostate cancer accounted for 29 % 
of all cancer cases in men. 
The vast majority of men diagnosed with prostate cancer are over the age of 50 
(Fig. 1).1, 2 In Norway during the years 2004-2008, 91.3 % of prostate cancer cases 
occurred in men aged 50 years or older.1 The mean age at prostate cancer diagnosis is 
72-74 years.2 Over the years the annual number of prostate cancer cases has increased. 
Since the five-year period 1956-60 to the five-year period 2001-2005 there has been a 
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five-time increase in the reported number of cases in Norway. This trend is worldwide 
and largely due to increased PSA testing since it became commercially available in 
1989, also in men who do not have any symptoms, and a growing and aging 
population. The Cancer Registry of Norway predicts that there will be an increase in 
annually reported cases of 50 % by 2020.3, 4 In terms of number of cancer deaths in 
2007, lung cancer ranks first in men (1224 deaths) closely followed by prostate cancer 
(1090 deaths; 19.3%). There has been a steady increase in the mortality rates since the 
1970s, but there is some evidence that recent mortality trends are more favourable, 
probably due to advances in early diagnosis, therapy and cancer care.1 Norway is one 
of the countries with the highest number of annual cases and deaths due to prostate 
cancer, but there is a general increase internationally as well. Prostate cancer accounts 
for approximately 10% of all malignant tumours in men worldwide. Incidences of 
prostate cancer vary widely between ethnic populations and countries, with the lowest 
rates in Asia and the highest in North America and Scandinavia, especially in African 
American people in the USA.2 Relative to Caucasians, prostate cancer incidence is 
66% higher in African Americans and 39% lower in Asian Americans.5 
 
 
Figure 1. Percentage distribution of cancer incidence by age in males, 2004-2008.                      
(Cancer in Norway 2008)1 
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AETIOLOGY AND RISK FACTORS 
 
The factors that contribute to an increased risk of or predisposition for prostate cancer 
are complex and not entirely understood. Both genetic dispositions, environmental 
factors including geographical location and diet and ethnic origin play a role in the 
elucidation of this complex picture. 
As mentioned above, there are ethnic variations concerning the risk of 
developing prostate cancer. Migration studies have shown that when people from low 
incidence areas (i.e. Japan) move to areas with higher incidence (i.e. USA), the 
incidence of prostate cancer increases, but the ethnic influence is still present. The 
increase is to about 50% of the rate for white Caucasians and to 25% of that for 
African-American people in the USA.6  
While most prostate cancers are sporadic, a hereditary predisposition to prostate 
cancer has been identified. Familial prostate cancer is estimated to account for 10% to 
20% of all cases of prostate cancer, and 5% to 10% of all cases are considered 
hereditary7, 8 and associated with early onset disease. The distinction between familial 
and hereditary prostate cancer relates to the number of family members and 
generations affected.8 Men with hereditary prostate cancer are diagnosed an average of 
6-7 years earlier than sporadic prostate cancer cases.9 Prostate cancer is genetically 
heterogeneous and several genes are likely to contribute to disease susceptibility. 
Hereditary candidate susceptibility genes with high penetrance have been identified, 
including HPC1/RNASEL, HPC2/ELAC2, HPCX, MSR1 and PCAP.10, 11 Linkage 
analysis based on genome-wide scans has mapped susceptibility loci for prostate 
cancer to chromosomes 1, X, 20, 17 and 8. Low-penetrance polymorphisms, in these 
genes and others, including the androgen receptor (AR), vitamin D-receptor, CYP17 
and SRD5A2, seem to play a role in the risk of developing prostate cancer.2 Also, men 
with germ-line mutations in the breast/ovarian cancer susceptibility genes BRCA1 and 
BRCA2 are at greater risk of developing prostate cancer, with a higher risk for carriers 
of BRCA2 than BRCA1 mutations.12, 13 Data from Iceland indicate that men with a 
mutation in BRCA2 are at particularly high risk of developing poorly differentiated, 
disseminated prostate cancer.14 
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Prostate cancer has been associated with a Western lifestyle, in particular a diet 
with a high intake of fat, meat and dairy products.2, 15-17 High intakes of –linolenic 
acid and calcium are associated with prostate cancer2, 18 while a high intake of phyto-
oestrogens (in for example soybeans) and anti-oxidative compounds like tomato-based 
products high in lycopene, and the micronutrients selenium, vitamin E (-tocopherol) 
and omega-3 fatty acids seem to reduce the risk of prostate cancer.19-24  
Androgens are important for the development of the normal prostate and 
withdrawal of testosterone is a well known and effective treatment for prostate cancer, 
but studies demonstrating the importance of varying androgen concentrations in 
prostate cancer are few and uncertain. Stattin et al. showed that high levels of 
circulating testosterone are not associated with increased prostate cancer risk.2, 25 High 
concentrations of the Insulin growth factor I (IGF-I), a peptide growth factor, increases 
the risk of prostate cancer and is proposed to represent a link between the western 
lifestyle and prostate cancer.  
 Viruses are known etiological agents accounting for approximately 20-25% of 
human cancers. Recently, the newly discovered gammaretrovirus xenotropic murine 
leukaemia virus-related virus (XMRV) has been identified in a percentage (0-27%) of 
prostate cancers with positive findings in the USA, but negative in European studies.26-
29 The incidence of the virus remains uncertain, but there seems to be a possible 
association between viral infection and prostate cancer, with different possible models 
of carcinogenesis dependent on whether epithelial or stromal cells are infected. The 
possible molecular mechanisms and etiological role in prostate carcinogenesis remain 
uncertain and needs to be studied further. 
 
  
THE PROSTATE AND CHARACTERISTICS OF PROSTATE CANCER 
The prostate 
In 335 B.C. Herophilus of Alexandria used the word ‘prohistani’ (Greek), which 
means ‘to stand in front of’, to describe the organ located ‘in front of’ the urinary 
bladder (Fig. 2). Although the existence of the prostate has been known for more than 
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two thousand years, accurate anatomical description of the gland did not appear until 
the Renaissance, with illustrations of the prostate and seminal vesicles by Regnier de 
Graaf around 1660.30  
 
 
Figure 2. A sketch of the anatomical location of the prostate gland in men. 
 
The prostate consists of three anatomical zones; the peripheral, transitional and central 
zone31 (Fig. 3). Few biochemical differences between the epithelial cells of the three 
zones have been demonstrated. 
 
 
 
 
 
 
 
 
 
 
Figure 3. An anatomical horizontal cross section of the prostate, displaying the three anatomical zones 
as well as the presence of cancer in the peripheral zone. (Picture courtesy by Lars A. Akslen and Ole J. 
Halvorsen). 
 
13 
The central zone does differ in containing a relatively large proportion of epithelial 
cells containing pepsinogen 2.32 Epidermal growth factor (EGF) receptors also seem to 
be present in a greater concentration in the central and transition zones than in the 
peripheral zone.  
 The prostate is an exocrine walnut-sized gland consisting of ductal-acinar 
structures embedded in stromal tissue.33 The acini are lined by well-differentiated 
secretory or luminal epithelial cells, which are androgen dependent and secrete 
proteins like Prostate specific antigen (PSA) into the lumen of the duct. These cells are 
surrounded by an underlying layer of proliferating non-secretory basal epithelial cells, 
that are primarily androgen independent and rest on the basement membrane, 
separating the epithelial cells from the surrounding stroma (Fig. 4). The basal cells 
express high molecular weight cytokeratines and p63, as opposed to luminal cells. 
Their absence is used as a marker of prostate cancer. In addition, rare neuroendocrine 
cells are present and are believed to be involved in the regulation of prostatic secretory 
activity and cell growth. The stroma surrounding the prostate is composed of smooth 
muscle cells, fibroblasts, lymphocytes and neurovascular tissue in a supporting 
extracellular matrix.34-37 
 
 
Figure 4. Three cell types in adult prostate epithelium. Basal cells (green) line the outside of the gland 
and reside against the basement membrane (black). Luminal cells (orange) contact the basal layer and 
the fluid-filled lumen. Rare neuroendocrine cells (red) are typically found in the basal layer with 
neurite-like extensions that can approach the luminal layer. (Goldstein et al., Mol. Oncol.,2010, 1-
12)35.  
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Characteristics of prostate cancer 
Most prostate cancers occur in the peripheral zone, less than 30% occur in the 
transitional zone and these have lower biochemical recurrence rates and are less 
malignant than tumours originating in the peripheral zone.38 The transitional zone is 
the predilection site of benign prostate hyperplasia (BPH). 
Prostatic intraepithelial neoplasia (PIN) which progresses to high-grade PIN 
(HGPIN) is considered the precursor lesion of prostate cancer.39-41 In HGPIN, the 
basal layer is present, but it shares otherwise many phenotypic similarities with cancer. 
HGPIN is characterized by benign prostatic acini and ducts, lined by cytologically 
atypical cells with prominent nucleoli in many cells, nuclear enlargement, nuclear 
crowding, an increased density of the cytoplasm and variation in nucleolar size. The 
volume of HGPIN has a positive correlation with the risk of cancer, tumour stage and 
Gleason grade.42, 43 Proliferative inflammatory atrophy (PIA) is described as discrete 
foci of proliferative glandular epithelium, with morphological appearance of simple 
atrophy or postatrophic hyperplasia occurring in association with inflammation.44, 45 
Etiological and pathological findings suggest that PIA may be involved in prostate 
carcinogenesis as maybe a very early precursor followed by HGPIN and malignant 
transformation,46, 47 PIA has also been suggested to represent the intermediate luminal 
cell type suggested to be the target of neoplastic transformation in prostate cancer.48 
The role of PIA in prostate cancer is uncertain and needs to be studied further. 
Recently, a model outlining the hierarchial relationship between the cells in the 
prostate epithelium was suggested35 (Fig. 5), with implications for the presumed cell of 
origin for prostate cancer. The cancer initiating cell type has remained unclear49 (Fig. 
6). Pathology observations, showing that more than 95% of prostate cancers express 
luminal markers with absence of basal cells, have led many to propose luminal cells as 
the source of prostate cancer (Fig. 6 – benign prostate tissue section to the left and 
prostate cancer tissue section to the right). The alternative stem cell hypothesis, 
however, proposes that a cancer stem cell might be the cancer initiating cell.50 A third 
scenario is that differentiation blockage at any intermediate developmental stage 
towards terminal luminal differentiation may give rise to cancer initiating cells. Very 
recently, strong evidence was presented that prostate cancer may originate among 
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basal cells51 and that the basal compartment and the luminal compartment may be 
capable of proliferating independently.52 Different possibilities are, however, not 
mutually exclusive, and further investigation into both normal lineage differentiation 
and prostate carcinogenesis is required.  
 
 
Figure 5. Proposed model for the prostate epithelial hierarchy. Stem cells within the basal layer likely 
give rise to multi-potent progenitor or intermediate cells that generate all three epithelial cell types. 
Evidence supports the existence of a luminal-restricted progenitor that can give rise to mature luminal 
cells. (Goldstein et al., Mol. Oncol.,2010, 1-12)35 
 
 
Figure 6. A schematic to illustrate alternative relationships between different epithelial cell types in 
the prostate gland as well as stained histological sections from prostate benign (left) and cancer (right) 
tissue from Rostad & Mannelqvist et al. (Paper I). 
Clinical and histopathological factors 
The initial TNM classification (before biopsy) and Gleason grading (after biopsy or 
surgery) are useful and widely applied prognostic tools in the assessment of prostate 
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cancer. The Gleason histological grading system, developed by Gleason in 196653 and 
later revised,54, 55 is based on the histological architectural pattern of the tumour (Fig. 
7).  
 
 
Figure 7. The Gleason grading system in which the sum of the two most prominent histological 
grades between one and five gives the Gleason score.56  
 
The grade is defined as the sum of the two most common growth patterns among five 
different patterns (grade 1-5) and reported as the Gleason score, thereby taking into 
consideration the heterogeneity of prostate cancer. This histologic grading is a 
powerful predictor of progression, and the prognosis of the cancer is more adverse 
with higher Gleason score.57, 58 The TNM classification (T-primary tumour; N-lymph 
node status; M-distant metastasis) is the most widely used system for prostate cancer 
clinical staging, in which stage T1 is clinically unsuspected prostate cancers, stage T2 
is prostate-confined cancer and stages T3 and T4 are tumours that transgress the 
boundaries of the prostatic gland (extension into the periprostatic tissue and/or seminal 
vesicle invasion (T3) with possible metastasis to other organs (T4)).59, 60 
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CHARACTERISTICS OF THE ETS-FAMILY OF TRANSCRIPTION 
FACTORS  
A transcription factor is any protein required to initiate or regulate gene transcription. 
The ETS family of nuclear transcription factors consists of approximately 30 
evolutionary conserved members in mammals, of which 27 have been identified in 
humans. The founding member of the ETS (E26 transformation-specific) (E-twenty-six 
specific) gene family, v-ets, was originally identified as a gag-myb-ets fusion 
oncogene of the avian transforming retrovirus E26, which induces both erythroblastic 
and myeloblastic leukaemia in chickens.61, 62 A characteristic feature of this family is 
that they share an evolutionary conserved winged helix-turn-helix DNA binding ETS 
domain of about 85 amino acid residues, which mediates binding to purine-rich DNA 
sequences with a central GGAA/T core consensus, the ETS binding site (EBS), and 
additional flanking nucleotides.63 It is one of the largest transcription factor families 
and based upon their structural composition and similarities in the ETS domain they 
are divided into 11 subfamilies (Fig 8).  
Most of the ETS-family members have the ETS domain in their C-terminal 
regions, although some have the domain in their N-terminal regions. In addition, a 
subset of ETS family proteins (ETS, ERG, ELG, ESE, TEL and PDEF) has another 
conserved domain called the Pointed domain (PNT) at their N-terminal regions, which 
forms a helix-loop-helix structure for protein-protein interactions. Some ETS proteins 
(TEL, ERF and TCF) contain a repressor domain and the majority (ETS, ERG, ELG, 
PEA3, ESE, SPI and TCF) contain a transcription activation domain (TAD).64-66 The 
ETS family of proteins displays distinct DNA binding specificities. The ETS domain 
and the flanking amino acid sequences of the proteins influence the DNA binding 
affinity, and alterations of single amino acids in the ETS domain can change its DNA 
binding specificities. 
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Figure 8. The ETS family of transcription factors. The main functional domains characteristic of 
members of each ETS sub family are depicted; alternative names for each member are given. 
Domains: AD, transcriptional activation domain; ETS, DNA binding domain; Pointed, basic helix–
loop–helix pointed domain; RD, transcriptional repressor domain. Protein abbreviations: E1AF, E1A 
enhancer binding protein; EHF, ETS homologous factor; ELF, E74-like factor; ELG, ETS like gene; 
ER81, ETS related protein 81; ERF, ETS repressor factor; ERG, v-ets avian erythroblastosis virus E26 
oncogene related; ERM, ETS related molecule; ESE, Epithelial specific ETS; ETS, v-ets 
erythroblastosis virus E26 oncogene homolog; ETV, ETS variant gene; FLI1, Friend leukemia virus 
integration 1; FEV, Fifth Ewing variant; GABP, GA repeat binding protein; LIN, abnormal cell 
lineage; MEF, myeloid ELF1-like factor; NERF, New ETS-related factor; PEA3, polyomavirus 
enhancer activator-3; PDEF, prostate derived ETS transcription factor; PSE, prostate epithelium-
specific ETS; SAP, Serum response factor accessory protein; SPDEF, SAM pointed domain 
containing ETS transcription factor; SPI, spleen focus forming virus proviral integration oncogene; 
TEL, translocation, Ets, leukemia; TCF, Ternary complex factor. (Gutierrez-Hartmann, TRENDS in 
Endocrinology and Metabolism; 18; 150-158; 2007)64 
 
ETS binding sites (EBS) have been identified in the promoter regions of viral and 
cellular genes, and ETS factors are involved in the regulation of expression of genes 
critical for proper control of cellular proliferation, differentiation, development, 
haematopoiesis, apoptosis, metastasis, tissue remodelling, angiogenesis, metastasis and 
19 
transformation. More than 400 ETS target genes have been postulated based upon the 
presence of functional EBS in their regulatory regions, 200 of which have been 
identified.62, 63, 67-72 
 Some ETS family proteins are expressed ubiquitously and some in a tissue-
specific manner. For example, ERG is initially expressed in embryonic endothelial 
tissues and later in the kidney, urogenital tracts and hematopoietic cells, while ETS2 is 
expressed ubiquitously.71  
 ETS family proteins regulate gene expression by functional interaction and 
complex formation with other transcription factors and co-factors on their DNA 
binding sites. Many ETS family proteins are downstream nuclear targets of the signal 
transduction cascades. Post-translational modification of ETS family proteins, for 
example by phosphorylation, modulates DNA-binding activities, association with co-
regulatory partners, transcriptional activation capacities, and subcellular localization.62, 
67, 71 Many ETS domain transcription factors are subject to autoregulation, during 
which their DNA binding activity is usually masked until an appropriate trigger and 
interactions with co-regulatory transcription factor(s) are in place. The ability of 
individual ETS factors to function as activators or repressors is also dependent upon 
promoter, co-factors and cell context.67 Unique combinations of protein-protein 
interactions direct different ETS factors to regulate the expression of specific target 
genes. A subset of ETS factors have repressor activity (e.g. ERF, YAN, TEL, NET) 
and may directly compete with other ETS factors for binding to EBS. For example, the 
transcriptional activity of ETS2 is inhibited by protein-protein interaction with ERG.73 
It has also been shown that ERG interacts with ESET (Erg-associated protein with 
SET domain), a histone H3-specific methyltransferase, thus participating in 
transcriptional repression.74 Unique promoter interactions with specific ETS factors 
have been demonstrated in the case of ETS2 (or ETS1) and ERG on the collagenase 
(MMP1) and stromelysin (MMP3) promoters. ERG appears to act as an activator of the 
collagenase promoter, while it inhibits stimulation of the stromelysin promoter by 
ETS2, whereas ETS2 stimulates both. In addition, interaction with other proteins can 
block the ability of ETS factors to activate transcription.67, 75 Overlap between specific 
protein-protein interactions may provide a mechanism to control the diverse functions 
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of ETS family. Such combinatorial control provides a mechanism to fine-tune the 
networks of cellular processes.   
Cellular responses to environmental stimuli are controlled by a series of 
signalling cascades that transduce extracellular signals from ligand activated cell 
surface receptors to the nucleus. There is a dynamic interplay between signalling 
pathways that results in the complex pattern of cell-type specific responses required 
for proliferation, differentiation and survival. Many of the ETS family proteins are 
downstream nuclear targets of the Ras-MAP kinase signalling pathway. They also 
interact with and influence crosstalk between specific cellular partners, which 
influence other signalling pathways such as the Jak/Stat, Smad and Wnt signalling 
pathways.71,76 ETS family members can act as both upstream and downstream 
effectors of signalling pathways. As downstream effectors their activities are directly 
controlled by specific phosphorylations, resulting in their ability to activate or repress 
specific target genes. As upstream effectors they are responsible for the expression of 
numerous growth factor receptors.76  
Among the first characterised interactions between ETS factors and another 
transcription factor, were studies demonstrating cooperativity between ETS factors and 
the AP1 (FOS/JUN) transcriptional complex to activate cellular responses by 
increasing the transcriptional activities of promoters containing AP1-EBS binding 
sites, including MMP1 (matrix metalloprotease-1 / collagenase), uPA (urokinase 
plasminogen activator), GM-CSF (granulocyte-macrophage colony stimulating 
factor), maspin (serpinB5) and TIMP-1 (tissue inhibitor of metalloproteinase-1). In 
contrast, MafB, and AP1 like protein, inhibits ETS1-mediated transactivation of the 
AP1-EBS sites.77 
ETS transcription factors and cancer  
Following the identification of ERG as being highly upregulated in a subset of prostate 
cancer patients,78, 79 ETS fusions have become one of the most common genetic 
markers of  prostate cancer.72, 80 The first clinically relevant candidates to dominant 
oncogenes in prostate cancer are ETS fusion genes resulting from chromosomal 
rearrangement of the 5’ untranslated region of the prostate-specific, androgen 
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responsive, Transmembrane serine protease gene (TMPSS2) to ERG, ETV1 (ER81), 
ETV4 (PEA3) or ETV5.80, 81 TMPRSS2:ETS gene fusions might be the most common 
genetic abnormality identified so far in human malignancies, resulting in androgen 
mediated induction of the respective ETS factors, which are then thought to activate a 
repertoire of ETS-responsive genes, leading towards prostate cell transformation.80 
Multiple genetic and epigenetic events may be required for cancer development. 
Oncogenes and tumour suppressor genes act as modulators of cell proliferation, while 
the balance of apoptotic and anti-apoptotic genes controls cell death. The hallmarks of 
cancer cells are: 1. independence from mitogenic/growth signals; 2. loss of sensitivity 
to “anti-growth” signals; 3. evasion of apoptosis; 4. induction of angiogenesis; 5. 
release from senescence; and 6. invasiveness and metastasis82 (Fig. 9).  
 
                       
Figure 9.  Acquired capabilities of cancer. (Hanahan and Weinberg,, Cell; 100; 57-70, 2000)82                          
 
 Oncogenic activation of cellular genes may occur through multiple 
mechanisms, including amplification and/or overexpression, activation by insertions of 
new regulatory sequences following retroviral integration, fusion with other proteins 
as a consequence of chromosomal translocations or through point mutations. ETS 
genes have altered expression patterns in both leukaemia and solid tumours, are 
chromosomally amplified or deleted, and are located at translocation breakpoints.72, 80 
As many ETS family transcription factors are downstream nuclear targets of Ras-MAP 
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kinase signalling, the deregulation of ETS genes may result in malignant 
transformation of cells.63, 68, 71 Since some ETS family proteins affect the expression of 
several oncogenes and tumour suppressor genes by direct regulation of their 
promoters, activation and repression, respectively, or by protein-protein interactions, 
and it is evident that they play important roles in cell proliferation, apoptosis and 
differentiation in normal cells, deregulated expression of ETS family proteins could 
lead to disruption of these processes and contribute to development and progression of 
malignant tumours.71 Several ETS family genes are expressed in the normal and/or 
cancerous prostate, including ETS1, ETS2, ELF1, ESE2 (ELF5), ER81 (ETV1), ERG, 
PDEF and PEA3 (ETV4). Advanced stages of prostate cancer are associated with 
expression of FLI1, ELF1, PDEF, ETS1 and ETS2. Transcriptional activation of ETS 
genes is essential for upregulation of extracellular matrix-degrading proteins including 
MMP1, MMP9, uPA, and the uPA receptor, many of which are associated with 
clinical features such as lymph node status and prognosis.72  
  The function of ETS family proteins has to be considered in combination with 
other cellular proteins, since the function of the same ETS protein sometimes differs in 
different types of tissues based on differences in cellular context.71 For example, 
expression of FLI1 is induced by ETS1 in endothelial cells but not in fibroblasts83, and 
ETS1 is involved in angiogenesis, but overexpression of ETS1 in umbilical vein 
endothelial cells induces apoptosis under serum deprived conditions.84  
 Individual ETS factors are overexpressed or downregulated in cancers. ETS2 is 
overexpressed in prostate and breast cancer, and this overexpression is necessary for 
transformed properties of the cancer cells. ETS1 expression is correlated with more 
malignant carcinomas and is a negative prognostic indicator.71 Conversely, PDEF 
expression is lost in many epithelial cancers.85 Among the multiple ETS target genes 
that are important for cancer progression are those that function in control of cell 
proliferation (cyclins and cdks), adhesion (cadherins, integrins, cell adhesion 
molecules (CAMs)), motility/migration (hepatocyte growth factor receptor c-Met, 
vimentin), cell survival (Bcl-2), invasion (uPA & uPAR, PAI, MMPs, TIMPs, 
heparanase), extravasation (MMPs, integrins), micro-metastasis (osteopontin, 
parathyroid hormone-related peptide (PTHrP), chemokine receptors (RANTES, MIP-
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3), CD44), and establishment and maintenance of distant site metastasis and 
angiogenesis (integrin 3, VEGF, Flt-1/KDR, Tie2).67, 71 Many known stroma-
modifying factors have known linkage to ETS factors. For example, ETS1 is a 
downstream effector of the epithelial mesenchymal transition (EMT) promoting 
hepatocyte growth factor (HGF), emanating from the stroma, while in tumour cells 
ETS1 and PEA3 can induce the expression of EMT markers such as vimentin and 
MMPs. ETS1 is also an activator of the HGF receptor c-MET, thus forming a positive 
feedback loop. ETS proteins can also mediate similar communication across different 
tumour and stroma compartments. VEGF, produced by tumour cells and fibroblasts, 
can induce ETS1 expression in endothelial cells.86 Concomitantly, ETS1, in 
cooperation with Hif-2, activates the transcription of VEGF receptor 2.87 Both ETS1 
and FLI1 are downstream effectors of, and are differentially regulated, by TGF, and 
these two factors have divergent functions in both fibroblasts and endothelial cells.  
Several ETS family proteins have been shown to be involved in the apoptotic 
process, and most members behave anti-apoptotically. For example, ETS2 and PU1 
rescue apoptosis in macrophages upon deprivation of macrophage colony-stimulating 
factor (M-CSF), through upregulation of anti-apoptotic Bcl-XL but not of apoptotic 
Bcl-Xs.88 FLI1 and ERG inhibit apoptosis in NIH/3T3 cells induced by serum 
depletion or treated with a calcium ionophore.89 Whether the ETS family proteins 
induce or prevent apoptotic cell death may depend on several factors such as 
expression levels, cellular contexts and the existence of agonistic or antagonistic 
signals in cells. ETS1 and ETS2 have been reported to be pro- as well as anti-
apoptotic. For example, expression of the p42 splice variant of ETS1 promotes Fas-
mediated apoptosis by upregulating caspase-1 in human colon cancer cells,90 and 
overexpression of ETS1 in human umbilical vein endothelial cells induces apoptosis 
under serum-deprived conditions.84 Overexpression of ETS2 in prostate tumour cells 
increases apoptosis accompanied by increased levels of p21WAF1/Cip1.91 There are 
several reports showing that ETS family proteins directly induce expression of 
apoptosis related genes. Expression of the Fas ligand gene in vascular smooth muscle 
cells is controlled by cooperative activation between ETS1 and Sp1,92 and the EBS of 
the 5’-flanking region of the caspase-3 gene is necessary to achieve sustained 
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transcriptional activity of caspase-3.93 FLI1 negatively regulates Rb expression by 
binding to an EBS in the promoter.94 It has also been reported that FLI1 enhances the 
bcl-2 promoter activity in leukaemic cells, thereby rescuing the cells from apoptosis.95 
 Several ETS transcription factors are preferentially expressed in certain lineages 
of hematopoietic cells and play crucial roles in their development and differentiation. 
Many are also aberrantly expressed, often due to chromosomal translocations, and play 
essential roles in the transformation and development of leukaemias. These includes 
PU1,96, 97 TEL, which is often a target for chromosomal translocations,98, 99 TLS-ERG 
in acute megakaryoblastic leukaemia (AMKL)100, 101 and ERG and ETS2 in myeloid 
leukaemia.102 The TEL (ETV6) gene, for example, is juxtaposed to several tyrosine 
kinase genes in leukaemias, including the platelet-derived growth factor receptor  
(PDGFR ) gene by [t(5;12)(q33;p13)] translocation in human chronic 
myelomonocytic leukaemias,103 the c-abl gene by [t(9;12)(q34;p13)] in chronic 
myelogenous leukaemias (CML) and acute lymphoblastic leukaemias (ALL),104 the 
Jak2 gene by [t(9;12)(p24;p13)] in T-cell and B-cell ALL,105 the TrkC/NTRK3 
(neutrophin-3 receptor) gene by [t(12;15)(p13q24)] in congenital fibrosarcomas,106 and 
ARG (c-abl related gene)/ABL2 by [t(1;12)(q25;p13)] in an acute myelogenous 
leukaemia (AML) line.107 All of the above-mentioned fused proteins possess the N-
terminal region including the pointed (PNT) domain for homo- and hetero-
dimerization from TEL and the intact tyrosine kinase domains from the partner 
proteins. Self-association through the PNT domain of TEL and subsequent activation 
of kinase activity of the fusion protein likely contributes to transformation of the 
cells.108  
The Ewing sarcoma (EWS) family of tumours share recurrent translocations 
that fuse the EWS gene from 22q12 to mainly FLI1, but also ERG (in approximately 
10% of EWS)109 ETV1, E1AF and FEV, all members of the ETS family of 
transcription factors. The N-terminal region of EWS, an RNA-binding protein, and the 
C-terminal region of FLI1, including the Ets domain, are fused forming EWS:FLI1 
t(11;22)(q24;q12) in 85% to 95% of the cases.110 They possess increased 
transactivation potential in comparison with the wild-type FLI1 gene and this activity 
is thought to contribute to malignant transformation of the cells. The EWS-ETS fusion 
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is causative in the development of Ewing's tumours, mainly due to the abnormal 
transcriptional regulation of key target genes which are involved in the regulation of 
cell cycle, signal transduction and migration.111 EWS and related tumours are 
characterized by elevated level of c-MYC expression. It has been shown that EWS-
FLI1 is a transactivator of the c-MYC promoter112 and is often associated with poor 
prognosis.113 The expression of EWS:FLI1 also leads to a considerable downregulation 
of the p57KIP2 tumour suppressor gene.114 In some cases of Ewing’s sarcoma, the EWS 
gene is fused with other ETS family genes including ERG, ER81/ETV1, FEV and 
E1AF.71,115
 
 
ERG  
 
ERG is most often referred to as ‘ets-related gene’, but also as ‘v-ets erythroblastosis 
virus E26 oncogene like’, ‘v-ets erythroblastosis virus E26 oncogene homolog’ or ‘v-
ets erythroblastosis virus E26 oncogene related’. In 1987, Reddy et al.116 isolated 
cDNA clones representing the complete coding sequence of an ets-related gene which 
they named ERG1, due to the fact that nucleotide sequence analysis of this 4.6 kb long 
cDNA, predicted a 363 amino acid protein, whose amino acid sequence showed a 
homology of approximately 40% and 70% to two domains corresponding to the 5’ and 
3’ regions of v-ets oncogene, respectively. Rao et al.117 identified ERG1 and another 
cDNA clone with alternative splicing, encoding a longer protein of 462 amino acids, 
named ERG2.  They proposed that the various isoforms are formed by alternative sites 
of splicing and polyadenylation, together with alternative sites of translation initiation. 
The identification of other isoforms followed.118, 119 ERG3 was characterized by a 
differential splicing which results in the insertion of 24 amino acids in the coding 
region of the ERG2 protein.119 All ERG isoforms can bind the ETS site in a specific 
manner and act as transcriptional activators, although they demonstrate differential 
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interactions with the AP1 complex (transcription factor consisting of jun/fos family 
proteins).120 
 The ERG gene has been localized to chromosome 21q22.2117, 121 which is part 
of the Down syndrome critical region (DSCR) of chromosome 21. The DSCR of 
chromosome 21 is abnormally triplicated in a subset of individuals with Down’s 
syndrome. Owczarek et al.121 determined that the ERG gene consists of at least 17 
exons spanning approximately 300 kb of genomic sequence, generating at least 9 
separate transcripts, of which the last 4 (ERG6 – ERG9) are likely of relatively low 
abundance. Only two of these transcripts encoded proteins that may have functions. 
ERG1 – ERG5 encode five proteins of 38 to 55 kDa, all of which bind DNA at ETS 
sites and act as transcriptional activators. They differ in their 5’ regions and the 
expression of two alternative exons, A81 (81 bp) and A72 (72 bp). Later we revised 
the exon maps of ERG1 and ERG2 (Paper I).79  
 During mammalian embryogenesis, ERG is first expressed in endothelium and 
later in the kidney, urogenital tract and hematopoietic cells, whereas down-regulation 
is observed following tissue differentiation.122, 123 The isoforms of ERG may form 
homodimers with itself or heterodimers with other ETS proteins including FLI1, 
ETS2, Er81 and PU1.120  
Isoforms ERG3 (p55) and ERG5 (p38) are the predominant forms expressed in 
endothelial cells.124 By in-situ hybridization we identified expression of ERG in 
prostatic endothelial cells but not in benign epithelial cells.79 ERG is involved in 
vascular development and angiogenesis as it regulates the expression of endothelial-
specific genes including von Willebrand factor, VE-cadherin, endoglin and 
intracellular adhesion molecule-2 (ICAM2).125-127  
 ERG is one of the ETS members involved in a number of chromosomal 
translocations in human leukaemias, including a [t(8;21)(q22;q22)] non-random 
translocation in patients with myelogenous leukaemia subtype M2 (AML-M2),128 a 
t(16;21)(p11;q22) translocation in human myeloid leukaemia fusing the ERG gene 
with the TLS/FUS gene129 and chromosomal rearrangement with the EWS gene in 
Ewing´s sarcoma.130 As Petrovics et al.78 and our group79 have shown, ERG is highly 
upregulated in around 50 % of prostate cancer patients. In 2005 Tomlins et al.80 
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identified the mechanism for this as a chromosomal rearrangement fusing the promoter 
region of the highly expressed androgen responsive serine protease gene TMPRSS2 
(21q21.3) to the ERG (21q21.2) coding sequence (either through deletion or 
translocation). Although genetic rearrangements through translocations are very 
common in leukaemias, they had so far not been identified in epithelial 
adenocarcinomas until Tomlins et al. 80 demonstrated ERG gene fusions in prostate 
cancer. This has become one of the most common genetic markers of prostate cancer 
and the first clinically relevant candidate to a dominant oncogene in prostate cancer, 
together with ER81 (ETV1), PEA3 (ETV4) and ETV5,81 which may alternatively be 
fused with TMPRSS2 in a minority of ETS fusion positive cases. A number of 
alternative 5’ and 3’ fusion partners have since been identified (Fig. 10). Although 
there have been opposing conclusions regarding the implications of this fusion, there 
seems to be an association between positive fusion status and adverse prognosis (Table 
1). 
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Figure 10. A sketch representation of the gene fusions characterized in prostate cancers so far. The 5' 
fusion partners are depicted on the left side and corresponding 3' partners on the right. Light colours at 
the ends of the genes depict untranslated exons. The dark-coloured boxes depict coding exons. The 
numbers on the boxes identify the base positions of the exons. The arrows represent androgen 
responsiveness of the fusion genes: arrows pointing up signify androgen-mediated upregulation; 
arrows pointing down represent androgen-mediated downregulation of the corresponding gene; the 
horizontal arrows represent absence of androgen action on the fusion genes' expression. TMPRSS2–
ETS gene fusions have been grouped as type I; other gene fusions which are androgen-inducible have 
been grouped as type II, androgen-repressed fusion genes make up type III, androgen-insensitive 
fusion genes, type IV, and lastly, the novel situation in prostate cancer cell lines, with ETS genes 
rearranged to an androgen-sensitive location (without the generation of classical gene fusions), has 
been classified as type V. (Kumar-Sinha et al., 2008. Recurrent gene fusions in prostate cancer. Vol 8 
(7):497-511131) 
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ETS gene status Assay Patient cohort Prognostic association Study
TMPRSS2:ERG 
rearrangement 
Break-apart 
FISH 
Prostate cancer, 
surgically treated, n = 96 
High-pathologic stage.  
132 
TMPRSS2:ERG 
fusion 
RT-PCR and 
DNA sequencing 
Prostate cancer, 
surgically treated, n = 
26, Gleason score 7 
Higher rate of recurrence.  
Single most important 
prognostic factor. 
 
133 
TMPRSS2:ERG 
fusion 
RT-PCR and 
DNA sequencing 
Prostate cancer, 
surgically treated, n = 
165 
Higher risk of recurrence. 
Strong prognostic factor 
independent of grade, stage and 
PSA level. 
 
134 
ERG rearrangement Break-apart 
FISH 
Prostate cancer, cohort 
of conservatively 
managed patients (no 
hormone treatment),       
n = 445. TMAs of 
transurethral resection 
Very poor cause-specific 
survival (25% at 8 years) (2+ 
Edel) compared with ERG 
rearrangement-negative cases 
(90% at 8 years). 
 
135 
TMPRSS2:ERG 
rearrangement 
Multicoloured 
fusion FISH 
Prostate cancer, 
population-based 
watchful waiting cohort, 
n = 111 
Prostate-cancer specific death.  
136 
TMPRSS2:ERG 
rearrangement 
Dual colour 
break-apart FISH 
Prostate cancer, 
hormone-naive and 
hormone-refractory 
lymph node metastases, 
n = 136 
Higher tumour stage, presence 
of metastatic disease involving 
pelvic lymph nodes.  
 
137 
TMPRSS2:ERG 
fusion 
FISH 
Break-apart 
FISH 
Prostate cancer, 
surgically treated, 
TMAs, n = 196 
Moderate to poorly 
differentiated tumours. 
 
138 
ERG 
overexpression 
Microarray,  
real-time PCR 
Prostate cancer, laser 
capture microdissected 
epithelial cells ERG-
overexpressing tumours 
Longer recurrence-free 
survival, well and moderately 
differentiated stages, lower 
pathological stage, and 
negative surgical margins. 
 
78 
TMPRSS2:ERG 
fusion 
RT-PCR and 
DNA sequencing 
Prostate cancer, TRUS-
guided needle biopsies,  
n = 50 
Lower Gleason grade and 
better survival than fusion-
negative tumours. 
 
139 
TMPRSS2:ERG 
fusion 
RT-PCR and 
DNA sequencing 
Prostate cancer, 
surgically treated, n = 54 
No correlation with clinical 
outcome. 
 
140 
TMPRSS2:ERG 
fusion 
 
 
 
RT-PCR and 
DNA sequencing 
 
FISH 
Prostate cancer, 
surgically treated, n = 54 
 
Hormone-naive pelvic 
lymph node metastases, 
n = 9 
No association with tumour 
stage, Gleason grade or 
recurrence-free survival. 
 
141 
2+Edel, deletion of 5’ERG sequences, accompanied by duplication of TMPRSS2:ERG sequences; FISH, 
fluorescence in situ hybridization; PSA, prostate-specific antigen; RT-PCR, reverse-transcription PCR; TMA, 
tissue microarray; TRUS, transrectal-ultrasound. 
Table 1. Prognostic associations of the TMPRSS2:ERG gene fusions. (Kumar-Sinha et al., 2008. 
Recurrent gene fusions in prostate cancer. Vol 8 (7):497-511131) 
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SIM2
 
 The SIM2 (Single-minded homolog 2) gene has also been identified within the 
Down’s syndrome critical region (DSCR) on chromosome 21 (21q22.2), which is 
associated with trisomy 21.142, 143 SIM2 was originally identified in Drosophila where 
it plays an important role in development and has peak levels of expression during the 
period of neurogenesis. Drosophila single-minded acts as a positive master gene 
regulator in central nervous system midline formation. SIM2 encoded proteins belong 
to a family of transcriptional repressors and may control brain developments and 
neuronal differentiation.144-147 Chen et al.,142 proposed that the human SIM gene is a 
candidate for involvement in certain dysmorphic features (particularly the facial and 
skull characteristics), abnormalities of brain development, and/or mental retardation of 
Down syndrome. Due to alternative splicing, the SIM2 gene exists in two distinct 
isoforms, SIM2-long (SIM2-l) and SIM2-short (SIM2-s).144 
 SIM2 has been shown to be involved in the pathogenesis of solid tumours. 
Higher expression levels of SIM2-s have been seen in the carcinomas of colon, 
pancreas and prostate in comparison to the normal tissues, but not in breast, lung or 
ovarian carcinomas or in most normal tissues (it is expressed in the kidneys and 
tonsils). Elevated expression has been seen in early colon adenomas and BPH as well, 
raising the possibility that the SIM2-s activation may be an early event. SIM2-s 
specific immunoreactivity was detected in the majority of tumours of different 
Gleason scores and in prostatic intraepithelial neoplasia (PIN), but not in most stromal 
hyperplasia.148 In our own gene expression profiling study, SIM2 ranked second 
among highly upregulated genes in prostate cancer.149 We also identified both SIM2-s 
and, for the first time, SIM2-l, as being upregulated in prostate tumour tissue compared 
with paired benign tissue samples.150 
 A proposed cancer-related role of the SIM family of genes is their ability to 
transcriptionally regulate key metabolic enzymes to inactivate carcinogens.151 SIM2 
belong to a family of transcription factors containg PAS (Per/Arnt/Sim) 
heterodimerization domains.148 The PAS domains are also cytosolic sensors that detect 
xenobiotics, redox changes, and light, oxygen and energy levels in prokaryotes and 
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eukaryotes.152 SIM2, if dysregulated (due to mutations, amplifications or loss of 
repression), could suppress xenobiotic-stimulated induction of Phase II enzymes by 
inhibiting the dimerization of aryl hydrocarbon receptor (Ahr) and Ahr nuclear 
translocator (ARNT) at one of their PAS domains.153 The resultant absence of the Ahr-
ARNT-mediated protective and homeostatic pathway would render cells vulnerable to 
mutagenesis and other forms of oxidative damage, and would provide an environment 
for tumourigenesis. The Ahr-ARNT heterodimer also mediates xenobiotic-induced 
apoptosis in foetal ovarian cells, by binding to the xenobiotic response element in the 
promoter region of the pro-apoptotic bcl-2 family member, bax.154 Therefore, 
suppression of Ahr-ARNT activation by SIM2 might disable apoptotic checkpoints 
that are essential for cancer surveillance. The precise function and nature of genes 
regulated by SIM2 are not completely clear. 
 Several groups have studied the expression of SIM2 in various cancers or cancer 
cell lines. DeYoung et al.155 made a systematic study of the expression differences 
among SIM family members in pancreatic cancer. In APAN-1, a pancreatic cancer-
derived cell line, antisense inhibition of SIM2-s expression caused a dose-dependent 
inhibition of SIM2-s mRNA. The targeted protein SIM2-s was also inhibited in the 
antisense-treated cells accompanied by growth inhibition and induction of apoptosis, 
providing a rationale for preclinical testing of the SIM2-s antisense drug in pancreatic 
cancer models. They identified both SIM2-s and SIM2-l isoform as expressed in lung, 
kidney, skeletal muscle, testis and tonsils. Low-level expression of SIM2-l was seen in 
the bone marrow as well. Real-time qPCR analysis of pancreatic tissues and cell lines 
showed expression of both SIM2 isoforms in tumours and tumour-derived cell lines. 
DeYoung et al.156 also found that antisense inhibition of SIM2-s in a RKO-derived 
colon carcinoma cell line caused growth inhibition, apoptosis and inhibition of tumour 
growth in a nude mouse tumorigenicity model. On the other hand, Kwak et al.157 
observed that SIM2-s expression was lost in human breast cancers, and Laffin et al.158 
found that loss of SIM2-s promotes epithelial mesenchymal transition (EMT) and 
tumourigenesis in breast cancer cells. Loss of SIM2-s caused aberrant mouse 
mammary gland ductal development with features associated with malignant 
transformation, and knockdown of SIM2-s in MCF-7 breast cancer cells contributed to 
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an EMT and increased tumourigensis. These changes were associated with increased 
SLUG (SNAI2) and matrix metalloprotease 2 (MMP2) levels. They suggested that 
SIM2-s is a key regulator of mammary-ductal development and that loss of expression 
is associated with an invasive, EMT-like phenotype. These results suggest that SIM2-s 
plays a key role in controlling normal EMT processes involved in mammary gland 
development and that loss of SIM2-s promotes pathological EMT associated with 
tumour progression. These tumour suppressor properties of SIM2-s in breast cancer is 
contradictory to its cancer promoting role in colon, pancreas and prostate cancers, and 
may reflect different tissue specific functions or differences in effect depending upon 
the cellular context. Increased expression of SIM2-s has also been identified in glioma 
and glioblastom cell lines,159 in which they were suggested to play a role in invasion, 
which may partly be associated with increased expression of TIMP2 and decreased 
expression of MMP2.  
DeYoung et al.156 showed that antisense inhibition of SIM2-s expression in a 
colon cancer cell line caused inhibition of gene expression, growth inhibition and 
apoptosis. Administration of the antisense, but not the control oligonucleotides, caused 
significant inhibition of tumour growth in nude mice with no major toxicity, 
establishing SIM2-s as a molecular target for cancer therapeutics.  
 
DIAGNOSTIC AND PROGNOSTIC BIOMARKERS OF PROSTATE CANCER 
 
Prostate cancer is a heterogeneous and multifocal disease and biomarkers are strongly 
needed to enable more accurate detection, improved prediction of tumour grade, and 
stage, as well as facilitated discovery of new therapeutic targets for improved 
treatment. 
 Currently, an important diagnostic and prognostic marker of prostate cancer is 
prostate specific antigen (PSA). Based upon initial concentration of total PSA in 
serum, prostate cancer is diagnosed by histological examination of prostate tissue 
obtained by ultrasound guided transrectal needle biopsy. This method has suboptimal 
sensitivity and specificity, leading to many unnecessary initial and repeat biopsies. 
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 Biomarkers may be detected in prostatic cancerous tissue and in body fluids 
(blood, serum, urine). Prostate tissue sampling requires an invasive procedure 
(transrectal ultrasound-guided biopsy) and the chances of sampling error represent a 
problem. It has been known since 1869 that cancer cells break away from the primary 
tumour and are present in body fluids.160 Serum and urine contain degradation 
products of extracellular matrix and of benign and malignant cells and their secreted 
products. Even in early cancer development, these cells are shed and may be 
detected.161, 162 For prostate cancer both blood (serum) and urine are viewed as 
attractive samples for diagnostic assays, due to the less invasive procedure compared 
with tissue sampling (Fig. 11). 
 
 
Figure 11. Blood / serum and urine prostate cancer markers have certain advantages over tissue 
prostate cancer markers. They may easily be obtained while prostate tissue sampling requires and 
invasive procedure (transrectal ultrasound-guided biopsy) (van Gils et al., Eur Urol; 48(6):1031-41, 
2005).162 
 
Early detection of prostate cancer has proved difficult and current detection 
methods are inadequate. At present, one of the major challenges in prostate cancer 
treatment is to distinguish between patients with aggressive and clinically significant 
tumours who need more intense treatment, and patients with indolent tumours, who 
will benefit from active surveillance. Novel biomarkers are strongly needed to enable 
more accurate detection of prostate cancer, improved prediction of tumour 
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aggressiveness and facilitated discovery of new therapeutic targets. Prostate cancer 
specific molecules have the potential to serve as diagnostic and prognostic indicators 
and therapeutic targets. The challenge lies in finding potential molecular biomarkers 
only present in prostatic cancerous tissue and not in benign tissue, which might be 
detected by noninvasive techniques in blood/serum or urine. The heterogenous and 
multifocal nature of prostate cancer must be taken into consideration. This is a 
challenge most likely solved with a combinatorial test in which detection of 
combinations of biomarkers confer higher specificity and sensitivity than todays’ PSA 
testing. Ideally, biomarkers of prostate cancer aggressiveness should be available at 
the time of diagnosis to allow optimal treatment planning.  
 In addition to diagnostic markers, prognostic, predictive, and therapeutic 
markers are needed to predict disease severity, choosing treatments, and monitoring 
responses to therapies, respectively. Guidelines for biomarker development have been 
established to aid in the validation of candidates.163, 164 There are several existing and 
potentially interesting novel prostate cancer biomarkers which confer increased 
diagnostic and prognostic information as well as improved sensitivity and specificity 
compared with PSA alone. 
PSA and PSA-derived forms  
 
Prostate specific antigen (PSA) was identified by Ablin et al. in 1970.165, 166 It is a 
seminal proteinase produced by normal and malignant prostate epithelial cells. PSA 
was originally used for monitoring prostate cancer patients and was subsequently 
implemented for screening purposes. Serum PSA testing has been used for over 20 
years as an aid in the diagnosis and management of prostate cancer and PSA is the 
most successful and widely employed cancer serum marker in use today. The 
measurement of total PSA has been shown to be useful as a prognostic tool, with high 
preoperative values being associated with advanced disease and a poor clinical 
outcome. PSA is a very sensitive marker, which enables us to diagnose prostate cancer 
before it manifests itself symptomatically or clinically. It is unclear, however, whether 
PSA screening has led to a decline in mortality due to prostate cancer.  
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The tissue specificity of PSA is responsible for its utility as a serum marker.167 
PSA is produced almost exclusively in the prostate, but an increase in serum PSA 
levels is not necessarily associated with cancer, it is not cancer specific. Although 
highly sensitive, it suffers from a lack of specificity, showing elevated serum levels in 
a variety of pathological conditions in the prostate including prostatitis, benign 
prostate hyperplasia (BPH), and non-cancerous neoplasia. Even though prostate cancer 
cells make less PSA than normal cells, PSA leakage around disrupted gap junctions of 
cancer cells causes elevated protein in the circulation.168-170 Many patients undergo 
unnecessary biopsies or treatment for benign or latent tumours. More than half of the 
men with a PSA over 4.0 ng/ml, which is the accepted clinical decision limit, are 
negative on initial biopsy.162, 171 On the other hand, there is strong evidence that a cut-
point of 4 ng/ml misses a significant number of cancers. In a prospective cohort study, 
designed to evaluate the preventive effect of the drug Finasteride, 15% of men enrolled 
in the untreated control arm of this trial, and who had an initial PSA 4 ng/ml harboured 
prostate cancer, with 14% of them showing high grade disease.172 The “PSA dilemma” 
population of men (those with elevated PSA who are negative on initial biopsy) are 
frequently biopsied multiple times as they age to assess the possible development of 
clinically significant cancers. For those men who are diagnosed and undergo curative 
surgical treatment, about 20-30% will clinically relapse, revealing that for many men 
cancer was not detected at an early enough stage. Nevertheless, 15-40% of the 
patients who undergo intended curative treatment for clinically localized PC will 
experience biochemical recurrence (i.e., a rise in serum PSA) within 5 years.173 
Systematic PSA screening has resulted in marked overdiagnosis and 
overtreatment of clinically insignificant tumours.174, 175 As an effect of PSA screening, 
the lifetime risk of prostate cancer diagnosis has increased to 16%, whereas the 
lifetime risk of dying from the disease is only 3.4 %. Further, during the last decade, a 
significant shift at radical prostatectomy has been observed, also called “stage 
migration”, which is related to the widespread use of PSA for screening. Tumours 
detected by PSA alone are characterized by small size, low grade, and they express 
low levels of PSA. There is, however, a very strong evidence of a highly significant 
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association between long-term cancer risk and PSA-levels in the blood measured at 
early middle age in representative populations of healthy men.169,176
 Measurement of total PSA has been shown to be useful as a prognostic tool, 
with high preoperative values being associated with advanced disease and a poor 
clinical outcome. It is unclear whether PSA screening has actually led to a decline in 
mortality due to prostate cancer. The relationship of PSA to tumour grade is also not 
clear. The tissue PSA concentration has been shown to decrease with increasing 
Gleason score, 177 although concentrations in the serum increase because of disruption 
of the basement membrane surrounding the prostate epithelial cells and in the overall 
prostate tissue architecture. Currently used routine prognostic tools (i.e., the Partin 
staging tables178 and the postoperative nomograms developed by Kattan et al.179 and 
Stephenson et al.179, 180) rely solely on pathological and clinical parameters, including 
serum PSA, Gleason score and tumour stage. These tools have limited utility for many 
patients who are mid-range, i.e. have serum PSA values in the range of 4-10 ng/ml. 
The inadequacies of PSA as a marker have created a need for novel markers of 
prostate cancer to prevent overtreatment of indolent tumours.  
PSA alternatives. PSA circulates in a number of distinct forms, and several variations 
have been studied as an alternative to the original total PSA test (for example 
evaluation of velocity, density, levels of free vs. bound proisoforms).168, 181-190 PSA 
processing is different in benign tissue and cancer tissue and measurement of these in 
addition to total PSA may significantly increase the diagnostic utility.162
   
Potential biomarkers 
A large number of potentially clinically useful biomarkers in prostate cancer have been 
investigated, some of which have been studied by our group and collaborators, and 
shown to be associated with adverse pathological parameters and of prognostic value 
in prostate cancer. These include loss of PTEN/p27 expression,191 increased expression 
of the p16 protein,192 strong EZH2 expression,193 high vascular proliferation194 as well 
as an association between the epithelial to mesenchymal transition (EMT), 
characterized by reduced E-cadherin and increased N-cadherin expression, and 
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prostate cancer progression.195 Table 2 provides a more comprehensive selection of a 
number of prostate cancer biomarkers which have been investigated, with various 
degrees of success. As previously mentioned, combinations of various biomarkers 
(multiplexed tests) are most likely to provide the necessary information needed, some 
of which studies are outlined in Table 3. The identification of the pathognomonic 
fusion between TMPRSS2:ERG and our ability to identify this gene product (mRNA 
detection) in tissue and urine of prostate cancer patients provide new hope regarding 
both more exact discrimination between grades of cancer and development of new 
therapeutic targets. This will be more closely covered under Discussion of results 
(Paper III).  
    Recently identified potential biomarkers are Sarcosine and Annexin A3. 
Sarcosine (N-methyl derivative of the amino-acid glycine) has recently been identified 
as a differentially expressed metabolite that is greatly elevated during prostate cancer 
progression to metastasis and it can be detected noninvasively in urine.196 Sreekumar 
et al.196 linked activation of the sarcosine pathway to AR and ETS gene fusion 
regulation. Both ERG- and ETV1-induced invasion were associated with a threefold 
sarcosine increase in benign RWPE cells. Knockdown of the ERG gene fusion in 
VCaP cells resulted in a more than threefold decrease in sarcosine with a similar 
decrease in the invasive phenotype. Androgen receptor and the ERG gene fusion 
product co-ordinately regulate components of the sarcosine pathway, and sarcosine is a 
potentially important metabolic intermediary of cancer cell invasion and aggressivity, 
making it a possible promising target for therapeutic interventions. Annexin A3 
(ANXA3) is negatively associated with prostate cancer.197, 198 ANXA3 protein 
expression is reduced in cancer providing a negative staining rate, which correlated 
with increasing pT stage and Gleason score. ANXA3 status was shown to be an 
independent adverse prognostic factor and ANXA3 may be detected in urine samples 
with improved specificity compared with PSA.  
 TMPRSS2:ERG gene fusions may also be detected in circulating prostate cancer 
cells. Mao et al.199 was unable to detect TMPRSS2:ERG transcripts by real-time qPCR 
in enriched cancer cells from peripheral blood from 15 patients with advanced 
androgen independent prostate cancer. However, they analyzed isolated circulating 
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cancer cells from 10 of these patients with FISH, and found TMPRSS2:ERG fusions in 
six of these cases. This suggests that cancer cells with the gene fusion may migrate 
into the blood vessel for seeding at distant sites. Analysis of circulating tumour cells 
may be used to monitor tumour progression and response to therapies,200 but further 
investigation is required to evaluate the application of the gene fusion in monitoring 
early stage disease.199 
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Table 3. Combination tests of potential biomarkers in prostate cancer
 
BIOLOGICAL 
SAMPLE
          
BIOMARKERS 
MARKER
MEASURED 
CLINICAL 
RELEVANCE 
             
REFERENCE 
Urine PCA3, GOLPH, 
SPINK1, 
TMPRSS2:ERG 
mRNA Detection and prediction 
of prostate cancer 
 
251 
Seminal fluid GSTP1, hTERT DNA,  
mRNA 
GSTP1 methylation and 
hTERT expression may 
help predict negative 
biopsies for men with 
elevated PSA levels. 
 
211 
Tissue E-cadherine, 
EZH2 
protein Increased EZH2:ECAD 
status associated with 
recurrence after radical 
prostatectomy. 
 
216 
Urine PCA3, 
TMPRSS2:ERG 
mRNA Detection and prediction 
of prostate cancer 
 
252 
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BACKGROUND AND AIMS OF THE STUDY 
Background and general aim 
The general aim of our study was to understand critical gene expression changes and 
regulatory patterns associated with prostate cancer, based upon new technological 
achievements and the possibilities for genome-wide analysis of gene expression. The 
hypothesis was that this discovery driven approach, in addition to increasing the 
understanding of prostate carcinogenesis, might result in novel diagnostic and 
prognostic markers. One long term goal of our research is to provide sufficient 
molecular information for individualized and tailored treatment options. 
 
Specific aims 
Paper I 
Based on initial gene expression analysis of prostate cancer by Halvorsen et al.,149 the 
aim of this study was to explore the expression profiles of prostate cancer with special 
focus on transcription factors. Differentially expressed genes in matched pairs of 
benign and malignant prostate tissue were identified and validated, with special focus 
on the ETS family of transcription factors, out of which ERG was the most 
consistently and highly upregulated member. 
 
Paper II 
In a previous study of gene expression profiles in prostate cancer,149 the transcription 
factor SIM2 was identified as being highly overexpressed in prostate cancer, and has 
also been proposed as a molecular target for cancer therapy. The aim of this study was 
to examine the expression status of SIM2 at the transcriptional and protein level as 
related to patient outcome in prostate cancer. 
 
Paper III 
The mechanism behind the overexpression of the transcription factor ERG (Paper I) 
was found by another group to be due to a recurrent gene fusion between the promoter 
region of the constitutively expressed gene TMPRSS2 and the coding region of ERG. 
 43
This generates a fused gene and transcript characteristic for prostate cancer. The aim 
of paper III was to determine the presence or absence of the nucleic acid fusions of 
TMPRSS2:ERG in urine samples from prostate cancer patients who underwent radical 
prostatectomy. Aspects important for optimal detection were examined. Possible 
correlations between fusion status and clinicopathological variables were also 
investigated. 
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MATERIALS AND METHODOLOGICAL CONSIDERATIONS 
 
PATIENTS SERIES AND TISSUES 
The patient series used in our studies include both archival paraffin embedded 
prostatic tumour tissue material, fresh frozen prostatic tumour and benign tissues as 
well as urine samples from patients prior to radical prostatectomy (Table 4).  
 
Table 4. Patient material 
Time period Sample No.
cases
No. 
samples
Histology Material Method Paper
1988 - 1994 RP tissue 104 104 Carcinoma Paraffin ISH II 
1997 - 2003 RP tissue 33 291 Carcinoma Fresh 
frozen 
Microarray I, II 
   23 Benign    
1997 - 2003 RP tissue 492 373 Carcinoma Fresh 
frozen 
qPCR 
ISH 
I, II 
   39 Benign    
2006 Urine 
Hamburg 
42 42 Carcinoma Fresh 
frozen 
qPCR III 
2006 - 2007 Urine 
Bergen 
13 13 Carcinoma Fresh 
frozen 
qPCR III 
119 tumour/benign pairs. 2Includes 33 cases from 1997-2003. 327 tumour/benign pairs. 
 
In 1984 radical prostatectomy was established at the Haukeland University Hospital in 
Bergen. Patients with localized prostate cancer were offered this treatment if they had 
a clinical stage T1/T2 disease, negative bone scan, general good health and 10 to 15 
years life expectancy. The earliest study population of 104 patients (median age 62 
years) were treated between 1988 and 1994, i.e. before the PSA era. PSA testing was 
introduced in Norway in the middle of the 1990s. The majority of the cancers in this 
series were clinical stage T2 (89%) and PSA detected tumours more typically seen 
today are clinical stage T1c.253 These tumours were also larger (median diameter 28 
mm) with more advanced pathologic stages than usually seen today.254 Fresh frozen 
prostate tissue samples were collected during 1997 – 2003 from an independent series 
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of 49 radical prostatectomies. The majority of these cancers were clinical stage T1c 
and median Gleason grade 6.2, in line with other findings after the introduction of PSA 
screening.253 
Urine sampling - Hamburg cohort: Through collaboration with the University 
Medical Centre Hamburg-Eppendorf in Hamburg, Germany, we received urine pellets 
and corresponding urine supernatants from 42 prostate cancer patients. The urine 
pellets were resuspended in a small volume of urine and TRK--mercaptoethanol was 
added before the pellets and supernatants were shipped to Norway on dry ice and 
frozen at -80 oC. These patients did not receive prostatic massage prior to sampling. 
Bergen cohort: In 2006 we started to collect urine samples after prostatic massage 
from all prostate cancer patients (who gave their consent) prior to treatment with 
radical prostatectomy at Haukeland University Hospital, Bergen. Each urine sample 
was divided into whole urine sample and pelleted urine sample with corresponding 
supernatant. Total RNA was isolated from both cohorts as well as genomic DNA for 
further studies according to protocols (Paper III). Table 5 summarizes clinico- and 
histopathological variables in the two cohorts. Studied together, 15 patients had 
Gleason scores of < 7, while 35 patients had a Gleason score of 7 and only 2 patients 
had a Gleason score > 7.  
 
Table 5. Clinico- and histopathological variables of the Hamburg 
and Bergen urine sample cohorts. 
 Hamburg cohort Bergen cohort 
No. of patients 42 13 
Mean (median) age at diagnosis 62.8 (64) 62.9 (63) 
Pre-treatment sPSA 7.5 (6.4) 7.4 (7.1) 
After treatment Gleason score   
 6 13 2 
 7 26 11 
Pathological stage (TNM-staging)   
T2 (pT2) 29 8 
T3 (pT3) 10 4 
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Archival tumour material 
Archival radical prostatectomy specimens were retrieved from the files of Department 
of Pathology, Haukeland University Hospital. From 1988, formalin fixed 
prostatectomy specimens were totally embedded and studied by whole mount step 
sections at 5 mm intervals by one pathologist (Ole Johan Halvorsen), and a 
representative area of 1-2 cm2 of highest tumour grade was selected retrospectively 
from the paraffin blocks of each specimen, and reembedded for further studies.  
 
Fresh tissue sampling 
From 1997 radical prostatectomy specimens were brought to the pathology department 
for fresh tissue sampling immediately following surgical removal. Guided by needle 
biopsy findings and palpation, the prostate was incised vertically and small 2-4 mm 
tissue specimens were dissected from macroscopic tumour and benign areas, snap 
frozen in liquid nitrogen and stored at -80 oC. Benign tissues were harvested from the 
contralateral zone. In support of this sampling strategy, gene expression patterns in 
benign tissues adjacent to tumour have been shown to be so substantially altered that it 
resembles a cancer field effect.255 Histopathologic confirmation of benign or tumour 
tissues and evaluation of tumour content were performed on HE (hematoxylin-eosin) 
slides on opposing sides of the dissected area. Tissue samples from presumed benign 
areas were excluded if malignant or dysplastic glands (PIN) bordered on or were seen 
in the vicinity of the dissected area. Tumour cases were selected for RNA extraction if 
more than 50% carcinomatous tissue were present (mean 76%).  
 
Clinicopathologic variables 
Several clinical variables were recorded for subsequent analysis: patient age at radical 
prostatectomy, date of primary diagnosis, date of prostatectomy, clinical stage (TNM-
classification as described in the Introduction), serum-PSA before and after surgical 
treatment, and complete follow-up information including date and time of eventual 
biochemical failure, as well as date and site of clinical recurrences, and survival. 
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Histopathologic variables 
The following variables were studied retrospectively: largest tumour dimension in the 
paraffin embedded specimen (measured as height or maximum dimension on the 
histological sections), capsular penetration, seminal vesicle invasion, involvement of 
surgical margins,59 presence of lymph node metastasis and pathologic stage. In line 
with recent recommendations,55 a modified Gleason grading was applied. Mean 
Gleason score for the 29 carcinomas selected for fresh frozen tissue sampling: 6.2 
(median 6, range 5-8). For validation purposes (qPCR), this series was expanded to a 
total of 37 malignant tumours and 39 benign samples, including 27 tumour/benign 
pairs. Although a high Gleason score is a significant determinant of prostate cancer 
death, there is an urgent need for additional biomarkers to increase the predictive 
value.256 
 
MOLECULAR METHODS 
 
Microarray and bioinformatics 
Global gene expression analyses performed by DNA microarrays have revolutionized 
the study of global analysis of gene expression in cancer patient samples and 
experimental models. The technology takes advantage of the fact that a fragment of 
each gene, the probe, can be positioned in a dot matrix on one single glass slide or 
chip. Hybrids formed between the probes and the solubilised targets of enzymatically 
modified and fluorescently labelled mRNA from experiments or patient samples can 
be recorded by means of high precision microarray fluorescence laser scanners and 
assisting computer software. In principle, the DNA microarray technology can 
quantify the entire gene expression pattern in a sample at a given moment based upon 
one single hybridization experiment. This powerful technology might resolve the 
underlying gene expression and regulatory patterns of normal cell differentiation and 
the aberrant patterns of disease. Even though this method has proven to be highly 
successful and useful, the global gene expression strategy still has its limitations and 
pitfalls, and may at times add more noise than elucidation to the discovery process.257 
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It is important to keep this in mind when analysing and interpreting the gene 
expression data.  
The microarray technology has been through a major development over the last 
decade. There are a number of commercial platforms available, for example 
Affymetrix, Illumina, Nimblegen and Agilent. The latter is the platform used by our 
group. The first microarrays developed were cDNA microarrays, and initially our 
group utilized a sequence-validated human cDNA library of 40 000 clones (40k) 
obtained from Research Genetics, originating from the IMAGE consortium.149 There 
are several challenges and potential sources of noise with cDNA-arrays, including 
wrongly annotated sequences and errors during maintenance of the cDNA library. 
Maintaining and handling a library of 40 000 cDNA clones with control over which 
specific sequences are present is difficult, and wrong annotations of the sequences are 
also a problem.257 These challenges make it difficult to compare results between 
different platforms (cross-platform comparisons)258 and it is estimated that up to 10-
30% of  cDNA probes were wrongly annotated. A method for updating the annotation 
of probe sets within a platform, based on sequence alignments and specific probe 
selection, was proposed by Dai et al.259 The platforms using synthetic oligonucleotide 
probes provide generally data of high-quality, with superior reproducibility compared 
with custom-spotted cDNA arrays,170 and by now oligonucleotide arrays have largely 
replaced the more unreliable cDNA arrays for the genome-wide study of human gene 
expression. Agilent now applies 60-mer microarrays, consisting of probes containing 
60 oligonucleotides for each gene. Around 60 nucleotide probe length provides 
optimal sensitivity and specificity, providing a balance between stability, sensitivity, 
specificity and possible problems with crosshybridization if the probe is too long, even 
though longer probes could be more sensitive for individual target genes.260 
Microarrays containing 44 000 (44k) reference sequences are currently available, 
covering all known genes and making it possible to examine the global mRNA gene 
expression in one sample. Therefore, due to the technological development, our first 
patient series was analysed using a cDNA microarray and later validated with 
oligonucleotide microarrays in an extended patient series. Another development is the 
present use of one-colour microarrays (only Cy3) instead of two-colour microarrays 
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(Cy3 and Cy5) as in our studies. An advantage of the two-channel system is that the 
reference sequence may cancel and correct for non-biological variations between 
samples. A disadvantage is that the ratios are dependent upon the expression levels in 
the reference sample. The one channel system generates absolute gene expressions 
which can be compared side by side. Cy3 is also a more stable fluorochrome than Cy5 
and makes the target easier to handle and less prone to ozone mediated damage and 
fading. 
Microarray. The Research Genetics human 40k cDNA microarray was printed 
at the Institute for Systems Biology, Seattle, and described by Halvorsen et al.149 The 
slides were scanned in an Axon Genepix Scanner according to protocol and GenePix 
Pro 4.0 was used for quality control and spotfinding. For validation purposes the 
patient series was expanded and the 21k Agilent human 1A oligonucleotide microarray 
was used. The oligonucleotide microarrays were scanned and features automatically 
extracted, recorded and analysed using the Agilent Microarray Scanner Bundle.  
Data analysis. Normalization, flooring or filtering of data was performed as 
described149 and the data was then formatted in a J-Express file suitable for additional 
data mining (normalization, statistical analysis, gene search and visualization of gene 
expression using clustering and other tools) (http://www.molmine.com/)261 (Fig. 12). 
The bioinformatics analysis of gene expression data remains a major challenge, and 
the software program J-Express was developed by the bioinformatics group at the 
University of Bergen, for analysis and visualisation of microarray data. To obtain 
consistency and reduce non-significant data, the genes were filtered before inclusion 
into the dataset (filtered dataset). Genes were included if the signal intensities in both 
channels differed by more than 2 standard deviations over background in at least 70% 
of samples in each class (for example T or B). Since filtering may exclude important 
candidate genes expressed only in subsets of samples (for example only detectable in 
T or B), as turned out to be the case for i.e. the ERG gene, another dataset based on 
flooring was generated (floored dataset). Here, a small, but constant value (in our 
dataset the value 20) was substituted for a missing signal in one of the two channels, 
ensuring that a possible strong signal in the second channel is being stored as a 
“floored” ratio instead of being filtered and removed. A number of bioinformatics 
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algorithms and statistical methods were applied to explore the gene expression 
signatures of our datasets and validate the results. We were interested in identifying 
differential gene expression in matched pairs of benign and tumour tissue. Following 
normalization a Cy5/Cy3 log2-ratio was calculated for each gene and an average fold 
change between T and B was calculated (2d - where d is the absolute difference of the 
average log ratio in T and B). The t-score (two-sample t-test) was determined for each 
gene, to quantify the distance of the average log-ratios between the groups compared 
to the spread of log ratios within each group. Paired and unpaired t-tests were also 
performed. The t-scores will be higher if the gene is much stronger expressed in T than 
in B or if a gene is consistently upregulated in T compared with B tissue. 
 
 
Figure 12. Pictures of the Agilent scanning equipment to the lower left, and a flowchart of the 
principle for data analysis and validation of gene expression data following microarray Cy5/Cy3 
scanning to the right. 
 
Polymerase chain reaction (PCR) and sequencing of PCR products 
In the Polymerase chain reaction (PCR) method, a pair of DNA oligonucleotide 
primers specific for the gene of interest, is used to hybridize with the sample DNA. 
The temperature of the sample is repeatedly raised and lowered to help the DNA 
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polymerase transcribe the target DNA sequence. The PCR reaction can be divided into 
three phases; the exponential phase during which there is an exact doubling of product 
accumulating at every cycle; the linear phase, during which the reactions start to slow 
down and the PCR product is no longer doubled at each cycle; and the plateau, at 
which no more products are being made and eventually the PCR products will begin to 
degrade. The plateau phase is where traditional PCR takes its measurements, also 
known as end-point detection. By comparing the intensity of amplified band on a gel 
to standards of a known concentration, semi-quantitative results may be achieved.  
 We found ERG to be highly overexpressed in a subgroup of our prostate cancer 
cases (Paper I), and we therefore wanted to investigate in more detail which of the 
ERG isoforms that were responsible for this increased expression. Conventional PCR 
was performed using a number of ERG specific forward and reverse primers followed 
by agarose-gel visualization of the resulting amplicon. In the course of this work it 
became obvious to us that the published exon mapping of ERG and its isoforms,121 did 
not match our findings. We therefore decided to sequence ERG ourselves. 
Conventional PCR and DNA-sequencing was used to characterize the exon structure 
of ERG1 and ERG2. ss-cDNA was made using ERG specific primers and then primary 
and nested PCR were performed, followed by PCR product clean-up (Qiagen protocol) 
and sequencing-PCR with BigDye buffer 3.1 (BigDye Terminator v1.1, Applied 
Biosystems). The sequence reactions were analysed on a 3100 Genetic Analyser 
(Applied Biosystems). Our publication (Paper I) is now referred to by Genbank 
concerning the corrected and revised exon organization of ERG1 (NM_182918) and 
ERG2 (NM_004449).  
 
Real-time quantitative PCR (qPCR) 
Gene expression changes observed in the microarrays need to be validated with an 
independent method to ensure that the observed changes are reproducible in a larger 
number of samples, and to verify that the array findings are not the result of problems 
inherent to the array technology, but truly reflect the differential gene expression in the 
samples. Real-time qPCR is a powerful and sensitive gene analysis technique used for 
a number of applications including quantitative gene expression analysis, genotyping, 
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SNP analysis, pathogen detection, drug target validation and for measuring RNA 
interference. Combined with reverse transcription we used the method for relative 
quantification of messenger RNA (mRNA) in cells and prostatic tissue samples for a 
number of genes, like AMACR, SIM2, ERG and other ETS-family members. Real-time 
qPCR has a higher linear dynamic range (and accuracy) than DNA microarrays, but 
the capacity for number of genes studied at the same time is more limited.  
 Unlike traditional PCR, which measures the amount of accumulated PCR 
product at the end of the PCR cycles, real-time qPCR measures PCR products as they 
accumulate during amplification. During the qPCR run two values are calculated. The 
threshold line is the level of detection at which a reaction reaches a fluorescent 
intensity above background in the exponential phase of amplification. The PCR cycle 
at which the sample reaches this level is called the Cycle threshold, the Ct-value. The 
Ct-value is used in downstream quantification of the PCR product. By comparing the 
Ct-values of samples of unknown concentration with a series of standards, the amount 
of template DNA in an unknown reaction can be accurately determined. 
 A number of platforms exist for real-time qPCR analysis. Our group utilizes the 
Applied Biosystems platform with the ABI 7900HT Sequence Detection System and 
SDS2.2 software for analysis of gene expression. In order to detect the accumulation 
of PCR products, Applied Biosystems utilizes two types of fluorescent reporter 
molecules based on two types of chemistry, TaqMan chemistry and SYBR Green dye 
chemistry. As the quantity of target amplicon increases, so does the amount of 
fluorescence emitted from the fluorophore, and we detect this increase in fluorescent 
signal. The SYBR Green dye is a highly specific, double-stranded DNA binding dye 
(minor-groove binder), which detects PCR product as it accumulates during the PCR 
cycles. Initially our group used the SYBR Green dye, but one disadvantage of this 
method, which reduces the specificity, is that it detects all amplified double-stranded 
DNA, including non-specific reaction products which may generate false positive 
signals. In Papers I to III we used the TaqMan based detection, which exploits the 
exonuclease activity of AmpliTaq Gold DNA polymerase by using a cleavable 
fluorescent probe in combination with forward and reverse PCR primers. This 
approach requires homology for both primers and the probe for producing a 
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fluorescent signal and is thus much more specific than the SYBR Green method. 
Primers and probes were designed according to Applied Biosystems guidelines for 
quantitative assays (ABI Real-time PCR systems Chemistry guide, P/N 7378658 Rev 
A) (Assays-by-design) or ordered as ready-to-use assays (Assays-on-demand). 
 During the PCR reaction, specific TaqMan primers and probe anneal to 
complementary sequences in the target gene ss-cDNA, the probe between the primers. 
The probe contains a reporter dye linked to the 5’-end of the probe and a 
nonfluorescent quencher (NFQ) at the 3’-end. When the probe is intact, the proximity 
of the reporter dye to the quencher dye results in suppression of the reporter 
fluorescence. During polymerization (extension) of the DNA strands, AmpliTaq Gold 
DNA polymerase cleaves the probes that are hybridized to the target. This cleavage 
separates the reporter dye from the NFQ, which results in increased fluorescence by 
the reporter. The principle for the primer and probe chemistry is illustrated in Fig. 13. 
The increase in fluorescence signal occurs only if the target sequence is 
complementary to the probe and is amplified during PCR. Additional reporter dye 
molecules are cleaved from their respective probes with each cycle, resulting in an 
increase in fluorescence intensity proportional to the amount of amplicon produced. 
The higher the starting copy number of the nucleic acid target, the sooner a significant 
increase in fluorescence is observed above the background. The amount of the nucleic 
acid target is measured during each amplification cycle of the PCR. An amplification 
plot graphically displays the fluorescence signal versus cycle number (Fig. 14). The 
Ct-value for each sample is the fractional cycle number at which the fluorescence 
passes a set threshold level. The amount of nucleic acid and the Ct-value are 
proportionally inversely related variables. By using an endogenous control, we can 
normalize quantification of the target gene for differences in the amount of total RNA 
added to each reaction.  
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 Figure 13. The principle of the TaqMan-probe based assay chemistry. An illustration of how the 5’ 
nuclease chemistry uses a fluorigenic probe to enable detection of a specific PCR product (ABI Real-
time PCR systems Chemistry guide, P/N 7378658 Rev A). 
 
 
 
Figure 14. Illustration of a single-sample amplification plot, showing terms commonly used in 
quantitative analysis. The amplification plot graphically displays the fluorescence signal versus PCR 
cycle number. (Ct: threshold cycle – the fractional cycle number at which the fluorescence passes the 
threshold; Rn : normalized reporter – the ratio of the fluorescence emission intensity of the reporter 
dye to the fluorescence emission intensity of the passive reference dye; Rn: the magnitude of the 
signal generated by the specified set of PCR conditions (Rn – baseline); Baseline: the initial cycles of 
PCR, in which there is little change in fluorescence signal; Threshold: A level of Rn that is used for 
Ct-determination. The level is set to be above the baseline and sufficiently low to be within the 
exponential growth region of the amplification curve. It is the line whose intersection with the 
amplification plot defines the Ct.) (ABI Real-time PCR systems Chemistry guide, P/N 7378658 Rev 
A) 
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The choice of an appropriate endogenous control is of vital importance for the 
normalization between samples and analysis of gene expression. The endogenous 
control is a gene present in each experimental sample and ideally should be expressed 
in equal amounts in each sample to be analyzed. -actin (ACTB), GAPDH and other 
housekeeping genes are commonly used, although expression may vary between 
samples and introduce bias. An evaluation of the most optimal endogenous control 
must be performed when designing the experimental protocol, and through this we 
found ACTB to be most optimal for our purposes. 
During relative quantification, a change in gene expression in a given sample is 
analyzed relative to another reference sample (the calibrator), for example an untreated 
control sample or gene expression in tumour samples relative to benign samples. We 
applied two alternative methods for relative quantification:  
Principle of the Standard curve method: The target and endogenous control 
amplifications are run in separate tubes, and this method requires the least amount of 
optimization and validation, but drawbacks are reduced throughput because wells are 
needed for the standard curve samples and errors in dilutions made in creating the 
standard curve which may affect the final results. All that is required of the standards 
is that we know their relative dilutions, and any stock RNA or DNA containing the 
appropriate target can be used. In papers I and II, serial dilutions of pooled prostate 
cDNA was found to generate good standard curves for the detection of ERG and SIM2 
and endogenous controls in our patient samples. Normalized gene target quantity for 
the sample is determined from the standard curves (the quantity of the target gene 
divided by the quantity of the endogenous control) and then divided by the normalized 
target quantity of the calibrator. The tumour samples are thus expressed as an n-fold 
difference relative to the calibrator (the benign sample in our experiments).  
Principle of the Comparative CT calculation method: This method also describes 
the change in expression of the target gene in a sample relative to a calibrator. It is 
similar to the standard curve method, except that it uses arithmetic formulas to achieve 
the results for relative quantification. The advantage of using this approach is that the 
need for a standard curve is eliminated. For the CT calculations to be valid, the 
efficiency of the amplification of target and endogenous control must be 
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approximately equal. The amount of target, normalized to an endogenous control and 
relative to a calibrator, is calculated using the formula 2-Ct.  
 Total RNA from patient tissues, cell cultures and urine samples (100 	l of 
whole urine, urine supernatant and pellet resuspended in 100 	l of whole urine after 
centrifugation at 1000 xg for 8 min) were isolated using the EZNA total RNA Kit 
(Omega Bio-tek) according to the manufacturer’s instructions. Prior to reverse 
transcription (ss-cDNA synthesis) the RNA was DNase treated, and ss-cDNA was 
synthesised according to Ambion instructions (MessageSensorTM RT Kit, catalog 
#1745, Instruction Manual). In the urine study (Paper III), genomic DNA was purified 
from 1 ml of whole urine (Bergen) or urine supernatant (Hamburg) using the Qiagen 
M48 Biorobot according to the manufacturers instructions for soft tissue (MagAttract 
DNA Mini M48 Handbook).  
Specific custom TaqMan gene expression assays (primers and probe) were 
designed (Assays-by-design) for the detection of the endogenous control -actin 
(ACTB), ERG isoforms (Paper I), SIM2 short and long isoform (Paper II) and two 
TMPRSS2:ERG transcripts (Paper III). Ready-made assays (Assays-on-demand) were 
ordered for an assay common to both SIM2 isoforms (Paper II) and the endogenous 
control GAPDH (Paper III). Real-time qPCR: Hexamer-primed ss-cDNA 
corresponding to 5-10 ng of prostate total RNA was used in each PCR reaction (Papers 
I and II). For each reaction in the urine study (Paper III), we used 2.5 μl of total RNA 
(as ss-cDNA) for the endogenous controls (-actin and GAPDH) and 7.5 μl total RNA 
for the TMPRSS2:ERG fusion transcript assays, to obtain optimal Ct-values. The real-
time qPCR reaction mixtures were prepared in 96-well optical microtiter plates and 
amplified in the ABI7900HT Sequence Detection System (SDS) (Applied Biosystems, 
Foster City, USA) according to protocol as described in Papers I to III. The SDS2.2 
software and Excel were used for analysis of relative gene expression using the 
Standard curve method (Papers I and II) or the Comparative threshold cycle (Ct) 
method (Paper III) according to program manuals and the ABI User Bulletin #2.  For 
the analysis of the urine samples (Paper III), normal female urine was used both as 
negative control and calibrator for the analysis. Samples with a real-time qPCR Ct-
value above 38 were considered to show no amplification and defined as negative. 
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This was supported by the observation that one of the duplicates showed poor 
amplification and often failed above this value. Laxman et al. 242 applied the same 
limit in their urine study.  
 TaqMan Low-density arrays (TLDA) are customizable 384-well microfluidic 
cards, allowing for simultaneous real-time qPCR for a large number of genes, greatly 
improving the efficiency of this method. Using TLDA the gene expression of a 
number of vascular markers and various ETS-family members were validated for 10 
prostate patient tumour/benign (T/B) pairs (Paper I). To validate the increased 
expression of SIM2-l isoform in tumour samples in the 96-well format, this isoform 
was included on a TLDA-card (Paper II). Each low-density array card was configured 
for 96 different genes in duplicates. ss c-DNA corresponding to 5 ng total RNA was 
diluted in TaqMan universal buffer and added to each loading well. The cards were 
prepared according to ABI guidelines and run at the same cycle parameters as 96-well 
plates before analysis were done by relative quantification using the SDS2.2 software. 
 All real-time qPCR samples were run in duplicates (TLDA) or triplicates 
(qPCR) for quality control and statistical verification. Negative controls (non-template 
controls (NTCs)) were also included on all plates and cards. Gene expression levels 
found by real-time qPCR corresponded well with, and validated, the microarray 
findings. We observed that expression ratios found between tumour samples and 
benign samples were compressed in the DNA microarrays compared with real-time 
qPCR, which is probably due to the fact that real-time qPCR has a much higher linear 
dynamic range than the microarray technology (106 vs 102-103) and this has previously 
been reported.260 
 
In-situ hybridization (ISH)
In-situ hybridization was performed both to validate our microarray and real-time 
qPCR findings of ERG (paper I) and SIM2 (paper II) mRNA expression in our cases, 
but also to provide information about their cellular locations. 
 In-situ hybridization, which preserves the histological morphology of the tissue 
sample, provides an advantage over extraction based techniques, since they are not 
able to take into account the heterogeneity of the prostatic tissue and distinguish 
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between gene expressions performed by the various cells present in the sample. Based 
upon the ability of nucleic acids to anneal to one another in a sequence specific 
complementary manner, and our ability to detect this annealing with labelled probes, 
this method identifies specific nucleic acids in situ in histological tissue samples, and 
therefore provides information concerning both the presence or absence of DNA or 
RNA and their location within the tissue sample, specifying the specific cell type 
responsible for gene expression and the location within the cell.262-264 In-situ 
hybridization provides excellent qualitative information, and a semi-quantitative 
evaluation of expression levels can be achieved by assessing staining intensity and 
frequency, although other methods like real-time qPCR are more optimal for 
quantification of gene expression.262 
  Archival tissues from patients are an invaluable resource to study and validate 
genes of clinical interest. One challenge of archival tissues is the fact that stored 
tissues are formalin-fixed and paraffin-embedded, which preserves the histological 
morphology, but can severely restrict the methods applicable for gene expression 
analysis.262, 263 In order for the probe to be able to reach its nucleic target, the tissue 
needs to be deparaffinised and the RNA unmasked by proteolytic digestion, which 
removes components of the cell nucleus and cytoplasm to allow probe access. The 
labelled probe may then hybridize with the target sequence before the visualization 
steps. Factors affecting hybridization efficacy and specificity are possible RNA 
degradation and crosslinking with proteins, degree of proteolytic digestion affecting 
the balance between probe penetration and destruction of cell and tissue architecture, 
specificity of the probe and the hybridization process and sensitivity of detection.263 
 Two types of probes are established for mRNA in-situ hybridization of paraffin 
embedded tissue, DNA oligonucleotide probes or RNA probes (riboprobes), and they 
may be radioisotope- (33P or 35S) or non-isotopic (e.g. Biotin or Digoxigenin) 
labelled.262, 263 Riboprobes are commonly used for RNA detection because RNA-RNA 
hybrids are more stable against denaturation than DNA-RNA hybrids. Riboprobe 
vectors can be used to generate both sense and antisense probes to allow control of 
hybridization, and unbound probe can be digested using RNase which does not digest 
double stranded hybridized RNA. DNA oligonucleotides may be used for the detection 
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of high abundance RNA. They have the advantage that they can be custom synthesised 
with high specificity and may be easily and efficiently labelled. Digoxigenin-labelled-
RNA probes (DIG-cRNA) may be generated by cloning (ERG in Paper I) or PCR 
(SIM2 in Paper II). When cloning, the probe sequence is cloned into a vector 
containing RNA polymerase promoter sites, and probe molecules are generated using 
phage RNA polymerase (T7, T3 or SP6) mediated incorporation of labelled 
nucleotides like digoxigenin-11-UTP. In the PCR method, labelled nucleotides may be 
directly incorporated or by using labelled primers.263  
 For in-situ hybridization of ERG (Paper I), histological tissue sections of cases 
with a high expression of ERG were selected. T3- and T7-containing Bluescript SK- 
ERG/-actin plasmids (Invitrogen) were used for synthesis of DIG-RNA ERG 
antisense, ERG sense (negative control) and -actin antisense probes (used as 
endogenous positive control), respectively. Plasmids were cut with restriction enzymes 
and then sequenced to verify the specificity of the sequence. Initially, short DNA 
oligonucleotide probes were designed, but they did not provide positive signals, 
possibly due to sensitivity limitations of short probes with less labelled groups than the 
Riboprobes. Cases expressing high levels of the SIM2-s isoform selected for in-situ 
hybridization as well (Paper II). SIM2-s antisense and sense and -actin antisense 
fragmented DIG-cRNA probes were made by the PCR-based approach. The method 
was carried out as described in Papers I and II (for ERG and SIM2 respectively) 
according to protocols. Slides of paraffin-embedded tumour tissue were deparaffinised 
and the RNA unmasked to allow probe access. Fragmented DIG-cRNA probes for 
SIM2 and ERG were diluted and incubated on the slides overnight. Post-hybridization 
wash was done twice before the slides were RNase treated (to remove unbound probe). 
Re-fixation of the slides was followed by blocking before incubation with anti-DIG-
AP Fab fragments (Roche). Staining was done by Liquid Permanent Red Chromogen 
(LPR) (Dako) and hematoxylin was used for counter staining. 
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IMMUNOHISTOCHEMISTRY AND TISSUE MICROARRAY (TMA) 
 
As with in situ hybridization, used for studying nucleic acids present in tissue samples, 
immunohistochemistry (IHC) is also widely used for in situ studies, studying protein 
expression patterns in histological samples thereby preserving the cellular morphology 
of the tissue samples, which is an advantage considering the heterogeneous nature of 
the prostatic tissue. Both in situ hybridization and immunohistochemistry are 
invaluable tools in combination with other molecular methods like DNA microarray 
and real-time qPCR when studying gene expression and potential biomarkers for 
cancer. 
 Immunohistochemistry may be performed on full sections of paraffin-embedded 
cancer tissue samples or using large scale tissue microarrays (TMAs), allowing high-
throughput molecular profiling of tissue specimens. Large scale expression analysis on 
tissues by TMA was introduced in the late 1990s, and each TMA contains a large 
number of cylindrical tissue cores from paraffin embedded full sections (donor blocks, 
each from a different patient) arrayed into a receptor paraffin block, which is then cut 
into potentially several hundred thin sections on a slide ready for various in situ 
methods applicable for nucleic acid detection or protein detection (ISH or IHC 
respectively).262, 265 The TMA technique has been validated in a number of studies, 
including prostate cancer,266 and immunohistochemistry based on TMA versus large 
sections of tissue show good concordance.267-269 The principle of the TMA method is 
illustrated in Fig. 15. 
 Protein expression of SIM2-s in prostate cancer tissue samples was studied with 
immunohistochemistry on tissue microarrays (TMAs). Previous studies on tumour cell 
proliferation by Ki-67 expression in “hot spot” areas on regular tissue slides270 as well 
as data regarding expression of p16 and p27191, 192, 271 were also included in the SIM2 
study (Paper II). 
 After formalin fixation, radical prostatectomy specimens were totally embedded 
and studied by whole mount step sections. Immunohistochemistry was performed on 5 
	m slides and the area of highest tumour grade was selected for tissue microarray 
construction, using three parallel cores (0.6 mm in diameter) from each case.191, 265, 272 
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Triplicates were used to account for both intratumour heterogeneity and problems with 
drop-outs. Epitope retrieval (necessary because of eventual masking or loosing of the 
antigen due to formalin fixation) was achieved by microwave treatment for 20 min in 
Tris-EDTA buffer at pH 9.0. Both monoclonal and polyclonal antibodies may be used 
for immunohistochemistry, in general however, monoclonal antibodies are preferred, 
due to their superior reproducibility and single specificity.273 The differences in 
epitope specificities of various antibodies as well as differences of the detection 
systems may influence the results. Challenges when optimizing standard protocols for 
individual IHC include that antigens may be “masked” or lost during formalin fixation, 
requiring different methods of antigen retrieval, and the various antibodies require 
different dilutions, optimal incubation periods and staining procedures. The 
immunohistochemistry for SIM2 was carried out according to protocol as outlined in 
Paper II. 
 
 
 
Figure 15. Tissue-microarray construction: (a) Slides and paraffin blocks of possible donor tissue are 
collected from the archive. (b) Tissue core biopsy of 0.6 mm in diameter is punched from a pre-
selected region of a donor block using a thin-wall stainless steel tube. A hematoxylin & eosin-stained 
section overlaid on the surface of the donor block is used to guide sampling from representative sites 
in the tissue. The tissue core is transferred into a pre-made hole at defined array coordinates in the 
recipient block. (c) Sections from a tissue microarray block are ready to be used for simultaneous in 
situ analyses. (Nocito et al., Int J Cancer: 94, 1-5.2001)274 
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STATISTICAL METHODS 
 
Statistical methods and analysis are invaluable, essential tools in all clinico-
pathological research. In our studies, statistical software packages used were BMDP 
(BMDP, Los Angeles), SPSS (SPSS Inc, Chicago) and J-Express (Molmine, Bergen). 
The most common methods for univariate survival analysis, the Kaplan-Meier 
product-limit method as well as the log-rank test, which may be used to test for 
differences between survival curves from various groups, were used.275 For 
multivariate survival analysis the most commonly used approach to regression 
analysis of survival data, the Cox’ proportional hazard regression model (likelihood 
ratio test) was used, including only significant variables (p < 0.05) from the univariate 
analysis.276  
 Associations were assessed with the appropriate methods for categorical or 
continuous variables. The following methods were applied:  Mann-Whitney U test 
(nonparametric rank test which examines the difference between two groups), 
Kruskal-Wallis test (nonparametric rank test which examines the difference between 
two or more groups), Pearson’s 
2 test (parametric correlation coefficient which 
measures the strength of the linear association between outcome and exposure 
variables), Fisher’s exact test (the preferred method when studying categorical 
variables in small groups), the Chi-X2-test (examines the association between two 
categorical variables in larger groups) and the paired and unpaired T-test (provides 
associations in small groups based on a normal distribution).276 The Spearman rank 
correlation test (Spearman rho test) was used to investigate possible correlations 
between continuous variables (nonparametric method based on ranks which calculates 
a correlation coefficient providing a measure of the strength of the association between 
two variables). 
Microarray gene expression analysis. In the analysis of gene expression data, 
a number of methods were used to compare gene expression between groups (paired 
and unpaired T-tests), prediction of gene profiles (Fishers linear discriminant), 
hierarchical cluster analysis to identify homogeneous groups based on gene expression 
(average linkage and Pearson’s correlation), testing of the predictability of gene 
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expression classifiers (i.e. T and B) (leave one out crossvalidation) and to test 
prediction accuracy achieved against pure chance (random permutations).149 
Statistical cut-off values. Sometimes continuous variables may be divided into 
subgroups forming categories for relevant statistical analysis. When doing this it is 
important to avoid cut-point selection bias, and this was done by categorization by 
median, quartiles or tertiles while considering the size of the subgroups, the frequency 
distribution and the number of events in each category.277 This categorization method 
was used for the analysis of expression studies and immunohistochemistry results, 
survival analysis and in grouping of the patients according to preoperative s-PSA (<4, 
4-10, 10-20, >20) (or median s-PSA),278 age (two groups with the age  63 or >63), 
pathological stage (two groups with  pT2 or  pT3) or by Gleason score (two groups 
with scores   6 and  7) for association and correlation studies. 
 
 
 64
MAIN RESULTS 
 
Paper I 
In Paper I we identified a number of genes differentially upregulated in tumour tissue 
compared with benign tissue, including previously described genes like AMACR and 
hepsin, as well SIM2, which was studied in more detail in Paper II, and ERG. The 
transcription factor ERG was found to be highly upregulated in a subset of prostate 
cancer patients (more than 20-fold upregulation in tumour samples (T) compared with 
benign samples (B) in approximately 50% of matched T and B tumour pairs). ERG1 
was identified as the predominant isoform expressed in prostatic tissue and ERG was 
shown to be expressed mainly in epithelial malignant tissue but also in vascular 
endothelial cells. The exon organization of ERG1 and ERG2 was also revised. The 
upregulated expression of the ETS-members ELF5, ETV1 and ETS1 was found to be 
inversely correlated with the overexpression of ERG, while ETS2 was moderately to 
strongly downregulated in most prostate cancers. Prostate tissue biopsies contain 
different cell types, including epithelial cells, stromal cells, endothelial cells and 
leukocytes in vessels and infiltrates. A very important result of this paper was to show 
by in situ hybridization that the abundant overexpression of ERG mRNA occurred in 
the epithelial cancer cells. Previously, ERG was known as an endothelial transcription 
factor, and the in situ hybridization was able to demonstrate ERG expression in 
endothelial cells although this was a minor contribution to the total ERG mRNA 
detected in cancer. 
 
Paper II 
In Paper II we validated the upregulation of SIM2 in prostate cancer. mRNA from 
both SIM2 isoforms, SIM2-s and SIM2-l, were shown to be highly upregulated in 
malignant tumour tissue compared with benign tissue. The SIM2-s protein was 
expressed in 44 of 103 prostate carcinomas (43%) and was associated significantly 
with preoperative serum PSA, high histological grade, extra-prostatic extension and 
increased tumour cell proliferation by Ki-67 expression as well as reduced expression 
of the p27 protein. A univariate survival analysis of 103 prostate cancer patients 
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showed a significant association between positive SIM2-s expression and reduced 
prostate cancer-specific survival. WHO histologic grade and SIM2-s expression were 
significantly associated with survival in a univariate analysis and only SIM2-s 
remained in a multivariate survival model as a significant independent predictor of 
reduced cancer-specific survival. 
 
Paper III 
In Paper III we were able to detect TMPRSS2:ERG gene fusion mRNAs in urine 
pellets from 19 out of 55 patients (34,5%) treated with radical prostatectomy. Gene 
fusion TMPRSS2:ERGa was identified in the majority of patients with a positive 
fusion status (89.5%), while TMPRSS2:ERGb was identified in a minority (36.8%) 
(7/19 positive cases). Five of these patients were positive for both fusion isoform a and 
b. Prostatic massage prior to urine collection improved the sensitivity of the test (69% 
positive cases in samples collected after prostatic massage vs. 24% positive cases in 
samples collected without prior massage). The highest detectable levels of gene fusion 
transcripts were found in total RNA from urine pellets collected after prostatic 
massage. The presence of the TMPRSS2:ERG gene fusion in urine was found to 
correlate with adverse clinicopathological variables, such as increasing s-PSA, high 
pathological stage and Gleason score 7 or higher. 
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DISCUSSION OF RESULTS 
Although there was initially (6 – 10 years ago) much scepticism to the potential, 
reliability and precision of the microarray technology, this methodology revolutionized 
global gene expression studies and is now widely applied in cancer research. 
Microarray studies analyze the genome-wide gene expression at a given time under 
certain conditions. An initial microarray gene expression study by Halvorsen et al.149 
provided us with a microarray data set used as a basis for the generation of gene lists 
of up- and downregulated genes in prostate cancer tissue compared with benign tissue, 
based on filtered (SIM2) or floored (ERG) datasets. Filtering of the genes before 
inclusion in the dataset may exclude candidate genes expressed only in subgroups of 
the samples. To compensate for this, the alternative method of flooring was also used. 
“Flooring” means to substitute a low and fixed value for either the denominator or the 
nominator when the hybridization signal is zero or close to zero in either channel. Both 
filtered and floored datasets were used for identification of differentially expressed 
genes. In the list of the differentially most upregulated genes based upon the floored 
dataset (Table II, Halvorsen et al.149) several unknown ESTs where highly ranked. 
ESTs (Expressed Sequence Tags) are short single-read transcript sequences of yet 
unidentified genes. The upregulated EST (IMAGE number 767130) (Table II, Paper I), 
exhibited full homology with the 3’ untranslated region of the ERG mRNA based upon 
BLAST analysis. Real-time PCR assays were designed for different regions of the 
ERG reading frame (ORF) and confirmed the very high overexpression of ERG in 
prostate cancer. The ETS family of transcription factors, and its member ERG in 
particular, was studied further in Papers I and III. The transcription factor SIM2 ranked 
second on the list of upregulated genes in the filtered dataset, after the already well 
known upregulated gene AMACR,279, 280 and was characterized further in relation to 
prostate cancer in Paper II. The majority of microarray gene expression studies of 
prostate cancer149, 232, 255, 279, 281-294 provide potential molecular signatures for prostate 
cancer vs. benign prostate, classification of moderate- vs. high-grade prostate cancer, 
prediction of PSA recurrence, tumour aggressiveness, predictive signatures, prediction 
of PSA recurrence etc. The search for clinically useful and applicable microarray 
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profiles and molecular biomarkers are ongoing, and the identification of ERG 
overexpression in half of all prostate cancer marks a new era in the understanding of 
prostate carcinogenesis. 
 
 
SIM2    
Based upon our initial microarray studies of  gene expression in localized prostate 
cancers compared with benign tissue,149 we decided to select highly differentially 
upregulated genes for validation and further studies. SIM2 ranked second on the gene 
list based on the filtered data set after AMACR (Table I in Halvorsen et al.149). We 
found that both the short and long isoforms of the SIM2 gene were expressed in benign 
prostatic tissue and that the expression was significantly upregulated in prostatic 
cancer tissue (Paper II). Tumour cell expression of the SIM2-s protein was shown to 
be associated with more aggressive clinicopathological features and reduced cancer-
specific survival. 
Although there are several microarray studies performed on prostate cancer, 
with the exception of one,295 none of them focus on or mention SIM2.255, 283-287, 295, 296 
But, when analyzing these studies in the publicly available gene microarray datasets 
within the Oncomine database,297 the data support our findings that the expression 
levels of SIM2 were significantly higher in prostate cancer tissue than in benign 
samples. The fold change of expression in tumour tissue compared with benign tissue 
varied between 2.5 to 65.8 in these studies according to Oncomine.  
SIM2 is a member of the PAS (Per/Arnt/Sim) family of transcription factors 
involved in regulation of key oxidative enzymes involved in carcinogen metabolism 
and cancer surveillance.148, 153 Although the exact molecular role and function of SIM2 
and pathways involved are not entirely clear, studies involving SIM2 in processes 
potentially involved in the carcinogenic processes are emerging. BNIP3 (HIF1-
dependent, hypoxically induced pro-apoptotic Bcl-2 BH3-only family member) has 
recently been identified as a novel target of SIM2-s.298 The SIM2-s mediated 
repression of BNIP3, which has recently emerged as a pro-autophagic factor, is 
coupled to the role of SIM2-s in increasing prostate tumour-cell survival during 
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prolonged hypoxic conditions. Aleman et al.,299 have found a possible link between 
SIM2-s and differentiation. In antisense-SIM2-s treated colon-cancer derived cells 
(RKO cells), the expression of a key stress response gene, growth arrest and DNA 
damage gene (GADD) 45, was found to be upregulated compared with normal cells, 
leading to subsequent apoptosis. Various apoptosis and differentiation-related genes 
were found to be up-regulated in the SIM2-s antisense-treated RKO cells. Key 
pathways, including GADD, caspase and p53 function, were identified as critical to 
the function of the SIM2-s gene. Li et al.300 proposed SIM2, as a candidate -
catenin/TCF target gene in Wilm’s tumours, since it contains at least one consensus 
TCF site in its promoter region, but states that additional studies will be necessary to 
validate SIM2 as a -catenin/TCF-responsive gene. Gravdal et al.195 however, did not 
find an association between SIM2-s and -catenin expression in the prostate cancer 
series. 
There are tissue differences both with regard to SIM2 up- or downregulation 
promoting or suppressing tumourigenesis and with regards to isoform preferences in 
both benign and malignant tissues.155, 157, 158, 301 SIM2-s is expressed in benign breast 
tissue and has been found to be downregulated in breast cancer derived cell lines and 
in human breast cancer samples, and linked to tumour suppressor activities, including 
decreased expression of matrix metalloprotease 3 (MMP3) and a role in the control of 
epithelial to mesenchymal transition (EMT). Loss of SIM2-s in MCF-7 breast cancer 
cells correlated to cell survival through the activation of SLUG-mediated EMT.157, 158 
These tumour suppressor properties of SIM2-s in breast cancer are contradictory to its 
upregulation of expression and oncogenic cancer promoting role in colon, pancreas 
and prostate cancers, and may reflect different tissue specific functions or differences 
in effect depending upon the cellular context.  
Previous studies found SIM2-s, but not SIM2-l, to be associated with pancreas, 
prostate and colon cancer, although not expressed in the normal tissues of these 
organs. Elevated expression of SIM2-s seen in early colon adenomas and in BPH,148 
raises the possibility that this activation may be an early event in tumourigenesis. In 
contrast, we found both SIM2 isoforms to be expressed in both benign and tumour 
tissue (Paper II), and indeed the ratio between expression levels in tumour tissue and 
 69
benign tissue was much higher for SIM2-l compared with SIM2-s (fold change 6.7 vs. 
3.9). This is the first study to identify SIM2-l as overexpressed in prostate cancer and 
the relevance of this isoform should be studied further. 
Our findings that SIM2 expression might be important for clinical progression 
of prostate cancer and associated with reduced prostate cancer-specific survival 
support the proposal of SIM2-s as a candidate for targeted therapy in prostate 
cancer.156, 302 Arredouani et al.,302 found that human HLA-A2.1 restricted SIM2 
epitopes induce specific T-cells in vivo, and that anti-SIM2 antibodies are detectable in 
the sera from prostate cancer patients. They suggest SIM2 as a prostate cancer 
associated antigen that is a potential target for prostate cancer immunotherapy. 
The precise function of genes regulated by SIM2, molecular pathways involved 
and the role of both SIM2-l and SIM2-s in prostate cancer are not clear and needs to be 
further elucidated, as well as its prognostic and therapeutic potential and utility.  
 
 
ERG AND OTHER ETS TANSCRIPTION FACTORS IN PROSTATE 
CANCER
 
Increased expression of ERG in prostate cancer 
The ERG gene was first described by Reddy et al.,116 in 1987, who suggested that ERG 
might be a member of the ETS oncogene family. Considering that ETS1 and ETS2 are 
translocated in certain leukaemias, they discussed the possibility of ERG being linked 
to any human malignancy either by amplification, translocation or other 
rearrangement. In Paper I, we identified ERG as one of the most highly upregulated 
genes in a large subset of prostate cancer patients through gene expression microarray 
analysis and validation with real-time qPCR. Approximately 50 % of our patient 
tumour tissue samples showed a high overexpression of ERG compared with benign 
tissue samples. This was a confirmation of the independent work done by Petrovics et 
al.,78 who in 2005 published ERG1 as being frequently overexpressed in the majority 
of prostate cancers. Since then several studies have confirmed the upregulation of ERG 
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in prostate cancer, ranging from 40-80% of prostate cancer patients being fusion 
positive.  
 
Exon organization of ERG
During the course of our work it became apparent that the published exon organization 
of ERG isoform 1 (NM_182918) and isoform 2 (NM_004449),121 did not match our 
experimental findings. Especially, when analyzing agarose gels run after PCR 
amplification across pre-mRNA splice sites, there was a discrepancy between the 
observed gel bands and the ones we expected according to Owczarek et al..121 A gel 
band of approximately 70 nucleotides present in ERG1 but not in ERG2, did not 
correspond with the assumed exon overview. We therefore undertook extensive 
sequencing of the ERG cDNA from benign prostate tissue, and based upon this we 
revised the exon organization of these two isoforms (Fig. 1, Paper I) and the relevant 
Genbank Accession numbers (NM_182918 and NM_004449) were corrected 
accordingly. The observed gel band corresponded to the 72-nucleotide exon 9 in the 
revised ERG1.  
 
Mechanism behind upregulated gene expression of ERG and other ETS family 
members
Later in 2005, Tomlins et al.,80 through a bioinformatic method called cancer outlier 
profile analysis (COPA), which analyses microarray data for marked overexpression 
of genes in subsets of cases, identified the two ETS transcription factors ERG and 
ETV1 as outliers and highly overexpressed in prostate cancer. COPA is useful to avoid 
that strongly expressed genes in subgroups go undetected, and in this respect serves a 
similar purpose as the “flooring” of gene expression data used in our studies. Without 
“flooring” both ERG and ETV1 would also have been filtered away in our microarray 
data. Importantly, Tomlins et al.80 identified the mechanism behind the observed 
upregulation of ERG, and also several other ETS transcription factors, in prostate 
cancer. The initial finding was that the promoter of the TMPRSS2 gene was fused to 
the ERG reading frame due to a chromosomal translocation or deletion. The TMPRSS2 
promoter is androgen-dependent and highly active in prostate luminal cells. This 
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translocation therefore results in strong aberrant activation of the ERG gene, which is 
silenced in benign prostate epithelium. They identified recurrent gene fusions of the 5’ 
untranslated region of TMPRSS2 also to ETV1, and suggested that the androgen-
responsive promoter element of TMPRSS2 drives the overexpression of ETS family 
members in prostate cancer. Although gene fusions, through translocations or 
interstitial deletions are very common oncogenic mechanisms in haematological 
tumours and sarcomas, as exemplified by the gene fusion BCR-ABL1 (Philadelphia 
chromosome) in CML,303 as well as the gene fusions between mainly FLI1 but also 
ERG and other ETS transcription factor genes and EWS in Ewing’s sarcoma,130 this 
finding was the first identification of a recurrent gene fusion in solid epithelial 
adenocarcinomas. The two alternative isoforms of TMPRSS2:ERG were called 
TMPRSS2:ERGa and TMPRSS2:ERGb (GenBank accession numbers DQ204772 and 
DQ204773 respectively), of which TMPRSS2:ERGa is the most prevalent one, and 
they were further analysed in our urine study (Paper III). The previous absence of 
identified gene fusions in common solid epithelial tumours like prostate cancer and 
breast cancer has been attributed to technical difficulties associated with their 
cytogenetic analysis.304, 305 Also, epithelial cancers are clonally heterogeneous, which 
makes it difficult to separate tissue with chromosomal aberrations from clinically 
irrelevant tissue. These recurrent gene fusions in prostate cancer were identified on the 
basis of gene expression data, thereby bypassing the technical limitations of 
cytogenetics in solid cancers.  
 The mechanisms involved in generating the double-strand break (DSB) that 
leads to the TMPRSS2:ERG gene rearrangements are not completely understood, but 
recently a proposed mechanism behind this was published,306 linking the generation of 
TMPRSS2:ERG fusions through DSBs to androgen stimulation. Topoisomerase II 
(TOP2B) is required for androgen-mediated gene expression and is recruited to the 
TMPRSS2 promoter by the androgen receptor (AR) which is induced upon luminal 
epithelial cell differentiation. Topoisomerases catalyze transient DSB as part of their 
normal activity, but dysfunction may lead to aberrant rejoining of DSB and resulting 
translocations. Both AR and TOP2B were highly coexpressed in TMPRSS2:ERG 
fusion positive neoplastic cells comprising prostatic intraepithelial neoplasia (PIN) 
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lesions. It was therefore hypothesized that androgen receptor signalling might lead to 
TOP2B-mediated DSBs and that such breaks could be involved in the generation of 
TMPRSS2:ERG fusions.  
 Since the first paper on the gene fusions was published,80 a number of different 
isoforms of TMPRSS2 and ERG gene fusions have been identified, as well as 
alternative 5’ partners for ERG, alternative ETS 3’ partners for TMPRSS2 and 
alternative 5’ partners for other ETS factors involved in recurrent gene fusions. A 
classification of ETS gene fusions in prostate cancer have been proposed.131, 307-309 
Most of the fusion genes and transcripts characterized so far have the protein coding 
region derived largely from the ETS gene, and in all fusion variants the ETS domain 
appears to be retained and the DNA binding domain preserved. The most common 
variants involve TMPRSS2 exon 1 or 2 fused to ERG exon 2, 3, 4 or 5.80, 138, 140, 141, 307, 
310-313 Less frequent combinations include TMPRSS2 exon 4 or 5 fused to ERG exon 4 
or 5313 and, in one case, TMPRSS2 exon 2 was found fused to inverted ERG exon 6-
4.312 These variant fusion transcripts most probably represent alternative splicing 
variants, and there are distinct phenotypic effects produced by different isoforms. The 
TMPRSS2:ERG fusion is found in approximately 90% of fusion positive cases, 
followed by ETV1 and ETV4 fusions, respectively. The reason for the observed 
frequencies of fusion partners with TMPRSS2 is unclear.314  
 
Differential expression of other ETS transcription factors 
Other ETS transcription factors were also differentially expressed, either up- or 
downregulated, in a number of our prostate cancer samples (Paper I). Our Agilent 
microarray expression data were available for 20 different ETS transcription factors. 
Most of the ETS factors did not show a differential gene expression in tumour tissue 
compared with benign tissue, we did find however, a negative correlation between the 
expression of ERG and ETV1, ETS1 and ELF5, i.e. some cases lacking ERG 
overexpression showed upregulation of these instead, suggesting that these 
transcription factors might substitute for ERG in prostate cancer. Whether genetic 
rearrangements are also responsible for the observed increased expression of ETS1 
and/or ELF5 in a subset of prostate cancers remains to be determined.  
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ETS2 was moderately to strongly downregulated in a majority of our prostate 
cancer samples. Both ERG and ETS2 are located on chromosome 21 (21q22.2-q22.3) 
only approximately 150 kb apart,117, 121 and it is likely that the ETS2 gene, which is 
located between TMPRSS2 and ERG, is lost in the process when the TMPRSS2 
promoter is fused to the ERG reading frame. The ETS transcription factors ERG and 
ETS2 may have competing roles in transcription complexes,73, 75 and the loss of ETS2 
could further promote ERG activity. The interactions between different ETS factors 
may have stimulatory or repressive effects on transcription. As one example, together 
with the AP1 transcription complex (FOS/JUN), ERG promotes collagenase-1 
(MMP1) activation and ETS2 promotes activation of stromeolysin-1 (MMP3). 
However, when ERG and ETS2 is coexpressed, ERG can bind to the stromelysin-1 
promoter and repress its activation by ETS2.73, 75 
One of our patients without increased ERG expression had instead a marked 
overexpression of ETV5. We suspected that this ETS factor could also possibly be 
involved in a gene fusion responsible for the upregulation, maybe with TMPRSS2. 
Exon-walking quantitative PCR identified an increased expression of the exons located 
towards the 3’-end of the gene compared with a 5’-end exon, suggesting the presence 
of a possible gene fusion. We performed 5’ RACE (5’ RNA-ligase-mediated rapid 
amplification of cDNA ends) and sequenced the 5’ end of the transcripts (unpublished 
work) in an attempt to identify a possible gene fusion partner. Unfortunately, this time 
consuming and challenging method revealed only the complete ETV5 nucleotide 
sequence, and we were at that time unable to identify any gene fusions. The reason for 
this is unclear, but could be due to one intact allele of ETV5 or contamination during 
PCR amplification by a normal ETV5 sequence. At the end of this work, Helgeson et 
al.,81 published the fusion between ETV5 and TMPRSS2 confirming our hypothesis, 
and we therefore did not go any further with this work. They also identified SLC45A3 
as an alternative 5’ partner for ETV5.  
 
Carcinogenesis 
Due to its high prevalence and recurrence in prostate cancer, it seems clear that 
TMPRSS2:ERG gene fusions play an essential role in the development of prostate 
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carcinogenesis. ETS factors have been reported to play an important role in extra-
cellular matrix remodelling and epithelial-to-mesenchymal transition (EMT) and their 
overexpression has been linked to increased motility, invasion and metastasis in 
various cancer models, as mentioned in the introduction. The actual role, and when in 
the malignant process the TMPRSS2:ERG gene fusions appear, is presently being 
thoroughly investigated. We suggested that the observed activation of ERG, or related 
ETS factors, might reactivate an embryonic proliferation program (Paper I). 
 The relationship between the epithelial luminal cells and basal cells in the 
prostate, both during development, in the adult and during cancer development has 
been discussed extensively, and the cancer initiating cell type has remained unclear. 
Pathology observations, showing that more than 95% of prostate cancers express 
luminal markers with absence of basal cells, have led many to propose luminal cells as 
the source of prostate cancer cells.315, 316 Crum et al.52 states that under normal 
conditions, there is little evidence that the basal cells of the prostate differentiate into 
secretory cells, and that both basal and luminal compartments appear capable of 
independent proliferation and self-renewal. This is contradictory to recent reports that 
prostate cancer may originate among basal cells.49, 51 Goldstein et al.,35 proposed an 
epithelial hierarchy of the normal prostate in which a stem cell within the basal layer 
of the normal prostate can give rise to multi-potent progenitor cells. This progenitor 
cell likely gives rise to neuroendocrine cells, mature basal cells and luminal-restricted 
progenitors that can generate mature luminal cells. They suggested that prostate cancer 
likely originates from a progenitor cell with multi-lineage differentiation potential or a 
mature cell that acquires this property. It could be that re-programming of basal cells 
and progeny causes them to differentiate in the direction of the luminal cell lineage 
and that prostate carcinogenesis in vivo is associated with differentiation towards 
mature luminal cells. This is consistent with the generally acknowledged loss of many 
basal cell markers and the presence of luminal cell markers in prostate cancer 
biopsies.51 Lawson et al.49 assessed the tumourigenic potential of different prostate cell 
subpopulations, and found that basal/stem cells were more efficient targets for 
transformation than luminal cells following the introduction of multiple alternative 
oncogenic stimuli.  
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   Emerging evidence suggests that the TMPRSS2:ERG gene fusion is an early 
event in human prostate tumorigenesis. ERG associated gene rearrangements and the 
resulting aberrant overexpression of the transcription factor may represent critical 
cooperative progression events in prostate tumourigenesis. ERG rearrangements have 
been identified in approximately 50% of localized cancers and 30% of metastatic 
cancers, but only in approximately 16-20% of PIN and HGPIN lesions.137, 307, 310, 317-320 
Genetic rearrangement of ERG is infrequently found in HGPIN and with the same 
ERG fusion pattern in the adjacent invasive prostate cancer.320, 321 However, the 
majority of prostate cancer specimens with ERG did not display this rearrangement in 
the associated HGPIN and there were no cases of ERG fusion in HGPIN associated 
with ERG negative cancers. Therefore, it seems likely that the TMPRSS2:ERG 
translocation is an early event in human prostate tumourigenesis associated with 
progression from HGPIN to cancer. Increased expression of ERG is found to increase 
invasion, but is not sufficient to drive the malignant transformation from HGPIN to 
cancer.319 However, forced expression of the androgen receptor, ERG and activated 
AKT1 can induce prostate cancer from basal cells.51 Deletion of all or part of the 
tumour suppressor gene PTEN (which is one way to activate the AKT pathway) is a 
frequent event in prostate cancer development (30%-70% of the cases) and PTEN loss 
and ETS gene rearrangements are proposed to be critically important and common 
molecular events in prostate carcinogenesis.80,319,321-322 Several authors319, 323, 324 have 
speculated that loss of PTEN or NKX3-1 may precede and cooperate with ETS gene 
fusions to drive cancer development from PIN to malignant cancer. King et al.322 
found that transgenic TMPRSS2:ERG mice developed PIN, but only in the context of 
PI3-kinase pathway activation, and suggested that additional events are likely required 
for actual malignancy. Yoshimoto et al.325 demonstrated that the co-occurrence of 
PTEN loss and ERG genetic rearrangement was a statistically independent predictor of 
biochemical failure after radical prostatectomy, and Carver et al.321 suggested that 
ERG targeted therapy may be effective at preventing the transition between HGPIN 
and invasive cancer, but this still remains to be studied further. 
Recently, Yu et al.,326 provided a link between the androgen receptor (AR), 
epigenetic regulation by polycomb and TMPRSS2:ERG gene fusions in prostate 
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cancer. They found that ERG disrupts AR signalling by inhibiting AR expression, 
binding to and inhibiting AR activity at gene-specific loci, and inducing repressive 
epigenetic programs via direct activation of the H3K27 methyltransferase polycomb 
protein EZH2, which has also been shown by Kundefranco et al.,327 who identified 
EZH2 as a target gene of ERG and ESE3. Interestingly, they showed that the AR and 
ERG co-occupy target genes, that there is an extensive overlap between AR and ERG 
binding sites, and they suggested that TMPRSS2:ERG plays a central role as a 
”malignant regulatory switch” that shuts down androgen signalling, thereby inhibiting 
normal prostate differentiation and inducing an epithelial stem cell-like 
dedifferentiation program that may be exploited during carcinogenesis. 
 
Screening
One of the major challenges in cancer diagnostics and treatment is to find genes and 
proteins specific for cancer and preferably not present in benign tissue, which ideally 
are of diagnostic use, provide information regarding prognosis and predictive 
information for choosing treatment options, as well as represent targets for clinical 
therapy. There is an urgent need for biomarkers capable of distinguishing between 
indolent tumours and aggressive tumours. Biomarkers that are specific for cancer and 
only present in cancerous tissue and never in benign tissue, are called pathognomonic 
(“characteristic for a particular disease”) biomarkers.  The current routinely used and 
dominating biomarker for prostate cancer is prostate specific antigen (PSA). One of 
the disadvantages of PSA, as discussed in the introduction, is the lack of specificity 
and sensitivity for prostate cancer. PSA is produced in benign as well as cancerous 
prostate cells, and elevated levels of PSA are present in benign conditions like BPH 
and prostatitis as well as in non-physiological conditions, for example following 
prostatic massage. The gene fusions between TMPRSS2 and ERG and other ETS 
transcription factors have only been identified in prostate cancer and the precursor 
stages PIN and HGPIN, and therefore these gene rearrangements are pathognomonic 
and extremely attractive potential biomarkers for clinical use as well as potential 
targets for therapy. The ability to detect these pathognomonic gene fusions in body 
fluids without the need for invasive strategies like biopsies is also an advantage. 
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 We analyzed our urine samples (Paper III) for the first two TMPRSS2:ERG 
isoforms identified, which are also among the most prevalent isoforms. We were able 
to detect TMPRSS2:ERG isoforms a and b in urine from prostate cancer patients taken 
prior to radical prostatectomy. We were very surprised when we identified the 
presence of more than one TMPRSS2:ERG gene fusion variant in one urine sample 
from five out of 19 fusion positive patients. Before our work on the urine samples was 
published, this observation was supported by the findings of others in both urine 
samples252 and prostate tissue samples.307, 328 Localized prostate cancer is typically 
multifocal, and various isoforms of the TMPRSS2:ERG gene fusion as well as other 
TMPRSS2:ETS variants may be identified in different foci of a prostate cancer,328-331 
reflecting the heterogeneity of the various foci present in a prostate cancer patient. 
This provides a challenge when screening for prostate cancer and deciding on the 
number of biopsies necessary to perform as well as how to analyse the results. Do the 
tumour clones from which the biopsies were taken reflect the true picture of the 
cancer? However, different sites of metastatic prostate cancer from the same patient 
are uniformly fusion-positive or fusion-negative.  
 Our ability to detect the TMPRSS2:ETS gene fusion products in body fluids like 
urine, provides both the possibility of easy noninvasive sampling and also circumvents 
the aforementioned challenge of multifocality and heterogeneity which has to be taken 
into consideration when performing and evaluating tissue sample biopsies. Since the 
first report of identification of the gene fusion in urine242 and the completion of our 
work, there has been published a number of papers regarding the identification of 
TMPRSS2:ERG and other potential prostate cancer biomarkers either alone or together 
in urine samples from prostate cancer patients (reviewed by Jamaspishvili et al.332), 
regarding diagnostic, prognostic and predictive purposes. Serum and prostatic fluids 
are also being evaluated. Urine sample detection relies on the fact that prostate cancer 
tumour cells are shed into the urine, and we demonstrated (Paper III) that the 
sensitivity of the detection of TMPRSS2:ERG greatly improved with prostatic massage 
prior to urine sampling.  
Hessels et al.252 calculated a score for the prostate specific non-coding RNA 
PCA3, which is highly upregulated in most prostate cancers, and found that a 
 78
combination of TMPRSS2:ERG fusion status and the PCA3 score improved the 
sensitivity for cancer diagnosis. Later, in a multiplex study of biomarkers in urine 
sediments using qPCR, Laxman et al.251 found that detection of GOLPH2, SPINK1, 
PCA3 and TMPRSS2:ERG fusion transcripts were significant predictors of prostate 
cancer, and outperformed serum PSA or PCA3 alone in detecting prostate cancer 
(sensitivity 66% and specificity 76%). Mao et al.,199 was able to detect the 
TMPRSS2:ERG fusion gene in circulating prostate cancer cells and suggested that it 
had a potential in monitoring tumour metastasis.  
A recent very interesting strategy to identify the presence of TMPRSS2:ERG 
gene fusions in prostate cancers, is the antibody-based detection of a truncated ERG 
protein by Park et al..333 They characterized a rabbit anti-ERG monoclonal antibody 
(clone EPR 3864; Epitomics, Burlingame, CA) using immunoblot analysis on prostate 
cancer cell lines, synthetic TMPRSS2-ERG constructs, chromatin 
immunoprecipitation, and immunofluorescence. ERG protein expression was 
correlated with the presence of ERG gene rearrangements in prostate cancer tissues 
using a combined immunohistochemistry (IHC) and fluorescence in situ hybridization 
(FISH) analysis. ERG expression was confined to prostate cancer cells and high-grade 
prostatic intraepithelial neoplasia associated with ERG-positive cancer, as well as 
vessels and lymphocytes. They detected ERG rearrangement prostate cancer with 
close to 100% sensitivity (96%) and specificity (97%). This study identifies a specific 
anti-ERG antibody and demonstrates association between ERG gene rearrangement 
and truncated ERG protein product expression. ERG protein expression may be useful 
for molecularly subtyping prostate cancer based on ERG rearrangement status. 
The usefulness of TMPRSS2:ETS gene fusions and other recently identified 
potential biomarkers, like Sarcosine (a metabolite)196 and Annexin A3 (ANXA3) 
(negatively associated with prostate cancer),197, 198 as clinically useful tests, either 
alone or in combinations with other biomarkers including PSA, needs to be studied 
further. Most likely specific and sensitive multiplex biomarker urine tests will be 
developed which hopefully provides more specific information and probably 
outperforms PSA alone in prostate cancer diagnosis and treatment.  
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Prognosis
TMPRSS2:ETS fusions may represent the most common recurrent structural aberration 
and gene fusion among all human malignancies. There are a great number of 
conflicting reports regarding possible associations between gene fusion status and 
patient outcome, but emerging data suggest that TMPRSS2:ERG positive cancers 
represent a subclass of prostate cancers that have a more aggressive nature and poor 
prognosis,131, 309 supporting our findings of a correlation between a positive 
TMPRSS2:ERG fusion status (Paper III) and adverse clinicopathological variables 
(increasing preoperative s-PSA, Gleason score  7 and high pathological stage), 
although we were the first to report an association between positive fusion status and 
increasing s-PSA (Paper III). These gene fusions have been variously associated with 
high pathological stage132 and higher rate of recurrence133 in independent cohorts of 
surgically treated localized prostate cancer cases, and the presence of gene fusion has 
been scored as the single most important prognostic factor.133, 134 In an assessment of 
gene fusion status in a population-based ‘watchful waiting’ cohort of men with 
localized prostate cancer, the TMPRSS2:ERG fusion positive subset of 15 % men was 
found to be significantly associated with prostate cancer specific death.136 In other 
studies, significant associations has been found between TMPRSS2:ERG rearranged 
tumours and higher tumour stage, as well as the presence of metastatic disease 
involving pelvic lymph nodes,137 more frequent gene fusions in moderate to poorly 
differentiated tumours as compared with well-differentiated tumours138 and a 
significant higher risk of recurrence (58.4% at 5 years) than fusion negative patients 
(8.1%).134  
Fusion of TMPRSS2 and ERG can occur through either translocation between 
both chromosome 21s or interstitial deletion (Edel) of the genomic material between 
TMPRSS2 and ERG.137, 140 Interestingly, observations suggest that the rearrangement 
through Edel represents an aggressive molecular subtype of prostate cancer.135, 137, 317 
However, many studies have reported a positive association or an absence of clinical 
correlation between the TMPRSS2:ERG fusion and prognosis.78, 139-141 Many of the 
negative reports have small sample sizes though, and more studies are needed with 
larger patient cohorts to resolve specific prognostic associations and assess the actual 
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clinical usefulness of the gene fusions. Phenotypic morphological associations of the 
gene fusions (and their variants) have been identified,334 but molecular associations 
require follow-up studies.  
 
General conclusions 
The discovery of the upregulation of the oncogene ERG in prostate cancer in 2005 is 
one of the major success stories of genome-wide microarray studies. The following 
discovery of the mechanism behind this upregulation due to the gene fusions between 
TMPRSS2 and ERG (or several alternative ETS transcription factors) and the progress 
in the elucidation of the biological functions and mechanism of ERG activity, have 
been of major importance in the ongoing understanding of prostate carcinogenesis. 
Representing pathognomonic biomarkers, it is likely that these gene fusions will be 
useful for the screening of prostate cancer and possibly also of prognostic or predictive 
use. A future issue is whether and how ERG and other ETS family members, or parts 
of their regulatory networks, may be utilized for the development of therapeutic 
molecular targets. 
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SPECIFIC CONCLUSIONS 
 
1.  The ETS family transcription factor ERG was identified as highly and 
consistently upregulated in prostate cancers. Approximately 50% of the prostate 
cancers showed 20-fold to more than 100-fold increased expression of ERG. 
Although endothelial cells expressed ERG, epithelial cancer cells were the main 
source of ERG expression. ERG1 was the predominant isoform expressed in 
cancerous tissue. (Paper I) 
 
2. Several ETS-family members were differentially expressed in cancerous tissue 
compared with benign tissue. ELF5, ETV1 and ETS1 were alternatively 
overexpressed in patients without increased ERG expression. Their increased 
expression was inversely related to ERGs, suggesting that these ETS 
transcription factors might substitute for ERG in prostate cancer. (Paper I) 
 
3. ETS2 was moderately to strongly downregulated in most prostate cancers. 
TMPRSS2, ERG and ETS2 are located on chromosome 21q22 and it is possible 
that the ETS2 gene is lost when TMPRSS2 is fused to ERG. Since ERG and 
ETS2 seem to have competing roles in transcription complexes, the loss of 
ETS2 could further promote ERG activity. (Paper I) 
 
4. It is possible to detect TMPRSS2:ERG mRNA transcripts in urine from prostate 
cancer patients. Isoform a (89.5%) was most prevalent compared with isoform 
b. Prostatic massage prior to urine sampling greatly improved detection of the 
fusion transcripts and thereby increased the sensitivity of the test. (Paper III) 
 
5.  More than one TMPRSS2:ERG isoform may be detected in urine from one 
patient, reflecting the heterogeneity of prostate cancer. (Paper III)  
 
6. The presence of TMPRSS2:ERG fusions in urine was significantly associated 
with adverse clinicopathological variables (preoperative s-PSA, Gleason score 
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and pathological stage). We were the first to show a positive association 
between fusion status and PSA levels. (Paper III) 
 
7. The transcription factor SIM2 was one of the most highly upregulated genes in 
prostate cancer, and both SIM2 isoforms, SIM2-long and SIM2-short, were 
highly overexpressed in cancer tissue. (Paper II) 
 
8. Expression of the SIM2-s protein in prostate cancer was significantly associated 
with adverse clinicopathological factors and reduced survival. SIM2 may be 
involved in the clinical progression of prostate cancer, and our findings support 
the proposal of SIM2 as a candidate for targeted therapy of prostate cancer. 
(Paper II) 
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